Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18187530,saccadic latency,"MK-0343 0.75 mg was equipotent with lorazepam as indicated by SPV (-42.4 deg/s), saccadic latency (0.02 s) and VAS alertness scores (1.50 ln mm), while effects on memory and postural stability were smaller.","Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18187530/),s,0.02,2379,DB00186,Lorazepam
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,4.30,4627,DB00186,Lorazepam
,4020675,half-life,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,2.51,4628,DB00186,Lorazepam
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],178,4629,DB00186,Lorazepam
,4020675,clearance,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],329,4630,DB00186,Lorazepam
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,65,4631,DB00186,Lorazepam
,4020675,volume of distribution,"Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS).",Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,69,4632,DB00186,Lorazepam
,4020675,Urinary excretion,Urinary excretion of acetaminophen glucuronide during 24 hr was decreased (84 +/- 9 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,84,4633,DB00186,Lorazepam
,4020675,excretion,260 +/- 21 mg of acetaminophen as glucuronide; P less than .001) and acetaminophen sulfate excretion was increased (323 +/- 25 vs.,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),,323,4634,DB00186,Lorazepam
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,33.0,4635,DB00186,Lorazepam
,4020675,half-life,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),h,14.3,4636,DB00186,Lorazepam
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],44.7,4637,DB00186,Lorazepam
,4020675,clearance,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),[ml] / [min],80.3,4638,DB00186,Lorazepam
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4639,DB00186,Lorazepam
,4020675,volume of distribution,Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS).,Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020675/),l,111,4640,DB00186,Lorazepam
,6127197,time to peak,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,2.99,10627,DB00186,Lorazepam
,6127197,elimination half-life,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,14.7,10628,DB00186,Lorazepam
,17635501,concentrations,"Median [95% confidence interval (CI)] LZP concentrations of 65.1 ng ml(-1) (50.2, 107.0) and 41.4 ng ml(-1) (22.0, 103.0) were attained within median (95% CI) times of 30 min (10, 40) and 25 min (20, 60) following i.v. and i.m. administration, respectively.",Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635501/),[ng] / [ml],65.1,12103,DB00186,Lorazepam
,17635501,concentrations,"Median [95% confidence interval (CI)] LZP concentrations of 65.1 ng ml(-1) (50.2, 107.0) and 41.4 ng ml(-1) (22.0, 103.0) were attained within median (95% CI) times of 30 min (10, 40) and 25 min (20, 60) following i.v. and i.m. administration, respectively.",Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635501/),[ng] / [ml],41.4,12104,DB00186,Lorazepam
,17635501,relative bioavailability,The relative bioavailability of i.m. LZP was 89%.,Pharmacokinetics and clinical efficacy of lorazepam in children with severe malaria and convulsions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17635501/),%,89,12105,DB00186,Lorazepam
,23720245,Cmax,"The Cmax, Tmax, t1/2, AUC0-24, AUC0-∞, MRT0-∞-1, 2.50±1.91 h, 7.61±2.81 h, 12.68±4.86 ng · mL-1 · h, 14.22±5.75 ng · mL-1 · h, 9.55±1.56 h, 12.81±7.94 L · h-1 and 121.70±32.70 L.",Pharmacokinetic study of icariside II after a single dose administration of YiGu capsule in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720245/),h,2.50,13083,DB00186,Lorazepam
,23720245,MRT0-∞-1,"The Cmax, Tmax, t1/2, AUC0-24, AUC0-∞, MRT0-∞-1, 2.50±1.91 h, 7.61±2.81 h, 12.68±4.86 ng · mL-1 · h, 14.22±5.75 ng · mL-1 · h, 9.55±1.56 h, 12.81±7.94 L · h-1 and 121.70±32.70 L.",Pharmacokinetic study of icariside II after a single dose administration of YiGu capsule in healthy Chinese volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720245/),[l] / [h],12.81,13084,DB00186,Lorazepam
,23720245,MRT0-∞-1,"The Cmax, Tmax, t1/2, AUC0-24, AUC0-∞, MRT0-∞-1, 2.50±1.91 h, 7.61±2.81 h, 12.68±4.86 ng · mL-1 · h, 14.22±5.75 ng · mL-1 · h, 9.55±1.56 h, 12.81±7.94 L · h-1 and 121.70±32.70 L.",Pharmacokinetic study of icariside II after a single dose administration of YiGu capsule in healthy Chinese volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720245/),l,121.70,13085,DB00186,Lorazepam
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.7,13549,DB00186,Lorazepam
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.2,13550,DB00186,Lorazepam
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],14.2,13551,DB00186,Lorazepam
,8646824,Plasma clearance,Plasma clearance was significantly greater in patients with cystic fibrosis for both lorazepam (1.7 +/- 0.4 versus 1.2 +/- 0.5 ml/min/kg) and indocyanine green (14.2 +/- 6.1 versus 9.1 +/- 3.0 ml/min/kg).,Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],9.1,13552,DB00186,Lorazepam
,8646824,clearance,"In contrast, the clearance of antipyrine was not significantly different (1.0 +/- 0.7 versus 0.8 +/- 0.3 ml/min/kg), but the formation clearance for 3-hydroxymethylantipyrine was significantly greater in patients with cystic fibrosis.",Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],1.0,13553,DB00186,Lorazepam
,8646824,clearance,"In contrast, the clearance of antipyrine was not significantly different (1.0 +/- 0.7 versus 0.8 +/- 0.3 ml/min/kg), but the formation clearance for 3-hydroxymethylantipyrine was significantly greater in patients with cystic fibrosis.",Hepatic drug clearance in patients with mild cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646824/),[ml] / [kg·min],0.8,13554,DB00186,Lorazepam
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00186,Lorazepam
,16143486,t(1/2a),"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),h,3.2,19281,DB00186,Lorazepam
,16143486,K(a),"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),1/[h],0.23,19282,DB00186,Lorazepam
,16143486,t(1/2),"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),h,10.4,19283,DB00186,Lorazepam
,16143486,beta,"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),1/[h],0.068,19284,DB00186,Lorazepam
,16143486,AUC(0-infinity),"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),,175.3,19285,DB00186,Lorazepam
,16143486,Cl/F,"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),[ml] / [minkg],2.6,19286,DB00186,Lorazepam
,16143486,Vd/,"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),l,F1,19287,DB00186,Lorazepam
,16143486,Vd/,"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),l,78.8,19288,DB00186,Lorazepam
,16143486,Fel,"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),%,0.3,19289,DB00186,Lorazepam
,16143486,Cl(R),"The data were fitted to two-compartment model and the pharmacokinetic parameters are reported as means (95% CI): t(1/2a) 3.2h (2.6-3.7 h), K(a) 0.23 h(-1) (0.19-0.28 h(-1)), t(1/2) 10.4h (9.4-11.3h), beta 0.068 h(-1) (0.061-0.075h(-1)), AUC(0-infinity) 175.3(ngh)/ml (145.7-204.8(ngh)/ml), Cl/F 2.6 ml/(minkg) (2.3-2.9 ml/(minkg)), Vd/F178.8l (146.5-211.1l), Fel 0.3% (0.1-0.5%), and Cl(R) 0.010 ml/(minkg) (0.005-0.015 ml/(minkg)).","Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143486/),[ml] / [minkg],0.010,19290,DB00186,Lorazepam
,7836548,clearance,Feeding increased the clearance of free lorazepam from 10.96 +/- 0.56 (mean +/- SD) to 14.11 +/- 1.21 mL/min/kg (P = 0.05) in patients with Gilbert's syndrome when examined in the presence of neo/chol.,"Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],10.96,20389,DB00186,Lorazepam
,7836548,clearance,Feeding increased the clearance of free lorazepam from 10.96 +/- 0.56 (mean +/- SD) to 14.11 +/- 1.21 mL/min/kg (P = 0.05) in patients with Gilbert's syndrome when examined in the presence of neo/chol.,"Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],14.11,20390,DB00186,Lorazepam
,7836548,Clearances,"Clearances, on the other hand, decreased with feeding in control Gilbert's patients (7.61 +/- 0.54 versus 8.82 +/- 0.48 mL/min/kg), although the differences were not significant (P = 0.09).","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],7.61,20391,DB00186,Lorazepam
,7836548,Clearances,"Clearances, on the other hand, decreased with feeding in control Gilbert's patients (7.61 +/- 0.54 versus 8.82 +/- 0.48 mL/min/kg), although the differences were not significant (P = 0.09).","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],8.82,20392,DB00186,Lorazepam
,7836548,clearances,"In contrast to both of these groups, feeding decreased lorazepam clearances (13.33 +/- 0.32 to 12.45 +/- 0.52 mL/min/kg, P = 0.17) in neo/chol-treated normals and increased clearances (9.95 +/- 1.84 to 12.38 +/- 2.05 mL/min/kg, P = 0.04) in control normals.","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],13.33,20393,DB00186,Lorazepam
,7836548,clearances,"In contrast to both of these groups, feeding decreased lorazepam clearances (13.33 +/- 0.32 to 12.45 +/- 0.52 mL/min/kg, P = 0.17) in neo/chol-treated normals and increased clearances (9.95 +/- 1.84 to 12.38 +/- 2.05 mL/min/kg, P = 0.04) in control normals.","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],12.45,20394,DB00186,Lorazepam
,7836548,clearances,"In contrast to both of these groups, feeding decreased lorazepam clearances (13.33 +/- 0.32 to 12.45 +/- 0.52 mL/min/kg, P = 0.17) in neo/chol-treated normals and increased clearances (9.95 +/- 1.84 to 12.38 +/- 2.05 mL/min/kg, P = 0.04) in control normals.","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],9.95,20395,DB00186,Lorazepam
,7836548,clearances,"In contrast to both of these groups, feeding decreased lorazepam clearances (13.33 +/- 0.32 to 12.45 +/- 0.52 mL/min/kg, P = 0.17) in neo/chol-treated normals and increased clearances (9.95 +/- 1.84 to 12.38 +/- 2.05 mL/min/kg, P = 0.04) in control normals.","Disposition of lorazepam in Gilbert's syndrome: effects of fasting, feeding, and enterohepatic circulation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836548/),[ml] / [kg·min],12.38,20396,DB00186,Lorazepam
,3197710,T1/2 lambda,"The derived pharmacokinetic parameters indicated a rapid distribution (median T1/2 lambda 1 i.v. = 15.2 min, median T1/2 lambda 1 oral = 31.6 min) into a steady-state volume of distribution approximating total body water, with a long elimination half-life and a low clearance.",Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: a pharmacokinetic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197710/),min,15.2,22192,DB00186,Lorazepam
,3197710,T1/2 lambda 1 oral,"The derived pharmacokinetic parameters indicated a rapid distribution (median T1/2 lambda 1 i.v. = 15.2 min, median T1/2 lambda 1 oral = 31.6 min) into a steady-state volume of distribution approximating total body water, with a long elimination half-life and a low clearance.",Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: a pharmacokinetic analysis. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197710/),min,31.6,22193,DB00186,Lorazepam
,3197710,Cmax,"The absorption of FDDF lorazepam was rapid in half of the patients and provided a high plasma concentration of lorazepam (Cmax = 61.8 ng ml-1) in a short time interval (Tmax = 58 min), but there were considerable inter-individual differences.",Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: a pharmacokinetic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197710/),[ng] / [ml],61.8,22194,DB00186,Lorazepam
,3197710,Tmax,"The absorption of FDDF lorazepam was rapid in half of the patients and provided a high plasma concentration of lorazepam (Cmax = 61.8 ng ml-1) in a short time interval (Tmax = 58 min), but there were considerable inter-individual differences.",Lorazepam fast-dissolving drug formulation (FDDF) and intravenous administrations as anaesthetic premedicants: a pharmacokinetic analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197710/),min,58,22195,DB00186,Lorazepam
,11307041,effective concentration (EC50),The mean values for calculated median effective concentration (EC50) derived from the pharmacokinetic and pharmacodynamic modeling of the different tests ranged from 11.3 to 39.8 ng/mL.,Pharmacokinetic and pharmacodynamic analysis of sedative and amnesic effects of lorazepam in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11307041/),[ng] / [ml],11.3 to 39.8,29618,DB00186,Lorazepam
,18806963,Extraction recoveries,Extraction recoveries were 72.3% for the drug and 79.1% for the internal standard.,High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806963/),%,72.3,32215,DB00186,Lorazepam
,18806963,Extraction recoveries,Extraction recoveries were 72.3% for the drug and 79.1% for the internal standard.,High performance liquid chromatographic analysis of rabeprazole in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806963/),%,79.1,32216,DB00186,Lorazepam
,3102240,half-life,"Plasma levels declined with a biphasic pattern, and the elimination phase had a half-life of 82.9 +/- 14.1 hours.",Pharmacokinetics of chlordesmethyldiazepam after single-dose oral administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102240/),h,82.9,32414,DB00186,Lorazepam
,3919752,elimination half-life,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),h,0.9 to 1.4,36181,DB00186,Lorazepam
,3919752,total plasma clearance,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),[ml] / [min],727 to 1440,36182,DB00186,Lorazepam
,8232,apparent first-order half-life,"Following a lag time, lorazepam was absorbed with an apparent first-order half-life of 15 min.",Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8232/),min,15,36618,DB00186,Lorazepam
,8232,peak plasma concentration,"The peak plasma concentration was 16.9 ng/ml, measured in the pooled sample drawn 2 hr after the dose, This corresponded to the time at which clinical effects appeared to be maximal.",Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8232/),[ng] / [ml],16.9,36619,DB00186,Lorazepam
,8232,apparent elimination half-life,The apparent elimination half-life of lorazepam was about 12 hr.,Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8232/),h,12,36620,DB00186,Lorazepam
,8232,renal clearance,Lorazepam glucuronide comprised 86% of urinary reactivity; its renal clearance was 37 ml/min.,Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8232/),[ml] / [min],37,36621,DB00186,Lorazepam
,30762,elimination half-life,"Blood levels decline thereafter, with an elimination half-life of about 12 hrs.",Clinical pharmacokinetics of lorazepam: a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30762/),h,12,39543,DB00186,Lorazepam
,19509,steady-state lorazepam level,"At daily doses of 6 mg per day, the mean steady-state lorazepam level was 88 ng/ml and that of lorazepam glucuronide was 170 ng/ml.",Clinical pharmacokinetics of lorazepam. Long-term oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509/),[ng] / [ml],88,44284,DB00186,Lorazepam
,19509,steady-state lorazepam level,"At daily doses of 6 mg per day, the mean steady-state lorazepam level was 88 ng/ml and that of lorazepam glucuronide was 170 ng/ml.",Clinical pharmacokinetics of lorazepam. Long-term oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509/),[ng] / [ml],170,44285,DB00186,Lorazepam
,2348383,maximum predicted effect (Emax),"The CNS effect measured by TRKN was characterized by a mean estimate of maximum predicted effect (Emax) of 418 with a t1/2keo of 0.43 hr, an estimate of effect site drug level to produce 50% of Emax (EC50) of 35.8 ng/ml and a power parameter (gamma) of 6.29.",Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348383/),,418,44639,DB00186,Lorazepam
,2348383,t1/2keo,"The CNS effect measured by TRKN was characterized by a mean estimate of maximum predicted effect (Emax) of 418 with a t1/2keo of 0.43 hr, an estimate of effect site drug level to produce 50% of Emax (EC50) of 35.8 ng/ml and a power parameter (gamma) of 6.29.",Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348383/),h,0.43,44640,DB00186,Lorazepam
,2348383,Emax (EC50),"The CNS effect measured by TRKN was characterized by a mean estimate of maximum predicted effect (Emax) of 418 with a t1/2keo of 0.43 hr, an estimate of effect site drug level to produce 50% of Emax (EC50) of 35.8 ng/ml and a power parameter (gamma) of 6.29.",Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348383/),[ng] / [ml],35.8,44641,DB00186,Lorazepam
,6105060,half-life,"In one dog, PAB levels reached a peak, which was low relative to that of other metabolites, at 1 hr after a single 5-mg/kg oral dose and decreased with a half-life of 1.2 hr.",Metabolism and disposition of peptido-aminobenzophenone (2-o-chlorobenzoyl-4-chloro-N-methyl-N-glycylglycinanilide) and its major benzodiazepine metabolites in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105060/),h,1.2,46643,DB00186,Lorazepam
,15685515,Blood flow,Blood flow through the 1.9-m 2 cellulose triacetate membrane filter was 180 mL/min.,Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[ml] / [min],180,49804,DB00186,Lorazepam
,15685515,Total-body clearance,"Total-body clearance was 6.4 L/h, and volume of distribution was 376 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],6.4,49805,DB00186,Lorazepam
,15685515,volume of distribution,"Total-body clearance was 6.4 L/h, and volume of distribution was 376 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),l,376,49806,DB00186,Lorazepam
,15685515,Ultrafiltration clearance,"Ultrafiltration clearance was 0.31 L/h, equivalent to approximately 5% of total clearance.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],0.31,49807,DB00186,Lorazepam
,15685515,plasma protein binding,"Average degree of plasma protein binding was 82.9% for lorazepam, with a sieving coefficient of 0.16 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,82.9,49808,DB00186,Lorazepam
,15685515,sieving coefficient,"Average degree of plasma protein binding was 82.9% for lorazepam, with a sieving coefficient of 0.16 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.16,49809,DB00186,Lorazepam
,15685515,degree of plasma protein binding,"For lorazepamglucuronide, degree of plasma protein binding was 39.5%, and sieving coefficient was 0.48 +/- 0.07.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,39.5,49810,DB00186,Lorazepam
,15685515,sieving coefficient,"For lorazepamglucuronide, degree of plasma protein binding was 39.5%, and sieving coefficient was 0.48 +/- 0.07.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.48,49811,DB00186,Lorazepam
,15685515,Total-body clearance,"Total-body clearance was 8.5 L/h, and volume of distribution was 157 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],8.5,49812,DB00186,Lorazepam
,15685515,volume of distribution,"Total-body clearance was 8.5 L/h, and volume of distribution was 157 L.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),l,157,49813,DB00186,Lorazepam
,15685515,Clearance by ultrafiltration,"Clearance by ultrafiltration was 0.055 L/h, equivalent to approximately 0.7% of total clearance.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),[l] / [h],0.055,49814,DB00186,Lorazepam
,15685515,degree of plasma protein binding,"Average degree of plasma protein binding was 95.8%, with a sieving coefficient of 0.04 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,95.8,49815,DB00186,Lorazepam
,15685515,sieving coefficient,"Average degree of plasma protein binding was 95.8%, with a sieving coefficient of 0.04 +/- 0.03.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.04,49816,DB00186,Lorazepam
,15685515,degree of plasma protein binding,"For the metabolite 1-hydroxymidazolamglucuronide, average degree of plasma protein binding was 43.4%, with a sieving coefficient of 0.45 +/- 0.06.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),%,43.4,49817,DB00186,Lorazepam
,15685515,sieving coefficient,"For the metabolite 1-hydroxymidazolamglucuronide, average degree of plasma protein binding was 43.4%, with a sieving coefficient of 0.45 +/- 0.06.",Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15685515/),,0.45,49818,DB00186,Lorazepam
,6133404,terminal (biological) half-life,The plasma concentration profile after intravenously administered lorazepam could in all cases be fitted by NONLIN to a biexponential function of time with a mean terminal (biological) half-life of 14.10 hrs +/- 2.94 S.D. (range 9.68 - 18.42 hrs).,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),h,14.10,50969,DB00186,Lorazepam
,6133404,half-life of the initial alpha-phase of distribution,The mean half-life of the initial alpha-phase of distribution was 0.31 hrs +/- 0.11 S.D.,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),h,0.31,50970,DB00186,Lorazepam
,6133404,apparent volume of distribution derived from AUC,"The mean apparent volume of distribution derived from AUC, Vd-area (=Vd beta), was 1.24 1 kg-1 +/- 0.17 S.D.",Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[1] / [kg],1.24,50971,DB00186,Lorazepam
,6133404,Vd-area (,"The mean apparent volume of distribution derived from AUC, Vd-area (=Vd beta), was 1.24 1 kg-1 +/- 0.17 S.D.",Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[1] / [kg],1.24,50972,DB00186,Lorazepam
,6133404,Vd beta),"The mean apparent volume of distribution derived from AUC, Vd-area (=Vd beta), was 1.24 1 kg-1 +/- 0.17 S.D.",Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[1] / [kg],1.24,50973,DB00186,Lorazepam
,6133404,plasma clearance,Mean plasma clearance of the drug was 62.17 ml kg-1 hr-1 +/- 8.85 S.D.,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[ml] / [h·kg],62.17,50974,DB00186,Lorazepam
,6133404,apparent central volume of distribution,The apparent central volume of distribution characterizing the open two-compartment pharmacokinetic model was 0.59 1 kg-1 +/- 0.19 S.D.,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[1] / [kg],0.59,50975,DB00186,Lorazepam
,6133404,biological half-life,"Mean biological half-life was 14.01 hrs +/- 2.31 S.D. and Vd-area 1.24 l kg-1 +/- 0.14 S.D., both values in full agreement with the findings based on intravenous administration.",Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),h,14.01,50976,DB00186,Lorazepam
,6133404,Vd-area,"Mean biological half-life was 14.01 hrs +/- 2.31 S.D. and Vd-area 1.24 l kg-1 +/- 0.14 S.D., both values in full agreement with the findings based on intravenous administration.",Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),[l] / [kg],1.24,50977,DB00186,Lorazepam
,6133404,Half-life of the absorption phase,Half-life of the absorption phase varied from 0.08 to 1.76 hrs.,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),h,0.08 to 1.76,50978,DB00186,Lorazepam
,6133404,systemic availability,Mean systemic availability of the drug was 88.8% +/- 8.3 S.D.,Pharmacokinetics and bioavailability of intravenous and intramuscular lorazepam with an adjunct test of the inattention effect in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6133404/),%,88.8,50979,DB00186,Lorazepam
,6111408,elimination half-life,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),h,5 to 15,51388,DB00186,Lorazepam
,6111408,volume of distribution,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[l] / [kg],0.6 to 2.0,51389,DB00186,Lorazepam
,6111408,clearance,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[ml] / [kg·min],0.9 to 2.0,51390,DB00186,Lorazepam
,6111408,elimination half-life,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),h,8 to 25,51391,DB00186,Lorazepam
,6111408,volume of distribution,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[l] / [kg],1.0 to 1.3,51392,DB00186,Lorazepam
,6111408,clearance,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[ml] / [kg·min],0.7 to 1.2,51393,DB00186,Lorazepam
,6111408,systemic availability,"Oral and intramuscular lorazepam are rapidly absorbed, with systemic availability averaging 90% or more.",Clinical pharmacokinetics of oxazepam and lorazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,90,51394,DB00186,Lorazepam
,6111408,free fraction,"Both oxazepam and lorazepam are extensively bound to plasma protein, but the free fraction for lorazepam (8 to 12%) is greater than that for oxazepam (2 to 4%).",Clinical pharmacokinetics of oxazepam and lorazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,8 to 12,51395,DB00186,Lorazepam
,6111408,free fraction,"Both oxazepam and lorazepam are extensively bound to plasma protein, but the free fraction for lorazepam (8 to 12%) is greater than that for oxazepam (2 to 4%).",Clinical pharmacokinetics of oxazepam and lorazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,2 to 4,51396,DB00186,Lorazepam
,17687269,AUEC_tracking,"Psychometric results were significant among the UGT2B7 genotype group (AUEC_tracking 261.5+/-298.9 in *1/*1, and 3,396.8+/-947 in *2/*2, P=0.047) when the two drugs were coadministered.",Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17687269/),,261.5,52633,DB00186,Lorazepam
,17687269,AUEC_tracking,"Psychometric results were significant among the UGT2B7 genotype group (AUEC_tracking 261.5+/-298.9 in *1/*1, and 3,396.8+/-947 in *2/*2, P=0.047) when the two drugs were coadministered.",Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17687269/),,"3,396.8",52634,DB00186,Lorazepam
,6116660,distribution,"In sham-operated dogs, lorazepam distribution was extensive (100 +/- 15.2 liters) and clearance approximately expected liver blood flow (971 +/- 91 ml per min).",Hepatic and extrahepatic glucuronidation of lorazepam in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116660/),l,100,57237,DB00186,Lorazepam
,6116660,clearance,"In sham-operated dogs, lorazepam distribution was extensive (100 +/- 15.2 liters) and clearance approximately expected liver blood flow (971 +/- 91 ml per min).",Hepatic and extrahepatic glucuronidation of lorazepam in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116660/),[ml] / [min],971,57238,DB00186,Lorazepam
,6116660,Urinary recovery,Urinary recovery of the conjugate in 5 hr was 45% of administered dose.,Hepatic and extrahepatic glucuronidation of lorazepam in the dog. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116660/),%,45,57239,DB00186,Lorazepam
,6116660,clearance,"Hepatic devascularization resulted in 39% reduction in distribution volume, and 89% reduction in clearance; however, there was still 105 +/- 88 ml per min of extrahepatic lorazepam clearance.",Hepatic and extrahepatic glucuronidation of lorazepam in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116660/),[ml] / [min],105,57240,DB00186,Lorazepam
,19947165,bioavailability,"In vivo absorption studies showed that intranasal absorption of lorazepam from microemulsions at 0.38 mg/kg had the larger AUC(0-t), the longer half-life and the prolonged circulation time with the mean bioavailability of 80.84% for ME2 and 63.48% for ME8 as compared to the intramuscular injection at 0.16 mg/kg.",Preparation of lorazepam-loaded microemulsions for intranasal delivery and its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947165/),%,80.84,57526,DB00186,Lorazepam
,19947165,bioavailability,"In vivo absorption studies showed that intranasal absorption of lorazepam from microemulsions at 0.38 mg/kg had the larger AUC(0-t), the longer half-life and the prolonged circulation time with the mean bioavailability of 80.84% for ME2 and 63.48% for ME8 as compared to the intramuscular injection at 0.16 mg/kg.",Preparation of lorazepam-loaded microemulsions for intranasal delivery and its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19947165/),%,63.48,57527,DB00186,Lorazepam
,16112623,flow-rate,"Chromatographic separation was performed on a reversed-phase Synergi Max RP analytical column (150 mmx4.6 mm i.d.; 4 microm particle size), using an aqueous mobile phase (10 mM KH2PO4 buffer (pH 2.4)-acetonitrile; 65:35%, v/v) delivered at a flow-rate of 2.5 ml/min.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ml] / [min],2.5,61951,DB00186,Lorazepam
,16112623,Retention times,"Retention times for OZP and LZP were 10.2 and 11.9 min, respectively.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),min,10.2,61952,DB00186,Lorazepam
,16112623,Retention times,"Retention times for OZP and LZP were 10.2 and 11.9 min, respectively.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),min,11.9,61953,DB00186,Lorazepam
,16112623,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) were 2.5 and 10 ng/ml, respectively, using 0.5 ml samples.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ng] / [ml],2.5,61954,DB00186,Lorazepam
,16112623,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) were 2.5 and 10 ng/ml, respectively, using 0.5 ml samples.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ng] / [ml],10,61955,DB00186,Lorazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,84.1,61956,DB00186,Lorazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,72.4,61957,DB00186,Lorazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,68.2,61958,DB00186,Lorazepam
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,9.4,66643,DB00186,Lorazepam
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,11.6,66644,DB00186,Lorazepam
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,141,66645,DB00186,Lorazepam
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,94,66646,DB00186,Lorazepam
,6144699,AUC,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),-1,65,66647,DB00186,Lorazepam
,6146348,tmax,"Lormetazepam was more rapidly absorbed from the soft gelatin capsule (tmax = 1.0 +/- 0.2 h) than from the tablet (tmax = 2.4 +/- 0.4 h), and the plasma concentration-time curve for the capsule was shifted to the left.",Pharmacodynamic correlates of modified absorption: studies with lormetazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146348/),h,1.0,72949,DB00186,Lorazepam
,6146348,tmax,"Lormetazepam was more rapidly absorbed from the soft gelatin capsule (tmax = 1.0 +/- 0.2 h) than from the tablet (tmax = 2.4 +/- 0.4 h), and the plasma concentration-time curve for the capsule was shifted to the left.",Pharmacodynamic correlates of modified absorption: studies with lormetazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146348/),h,2.4,72950,DB00186,Lorazepam
,8263762,day-time,The day-time steady-state clearance of free lorazepam measured 7.55 +/- 1.95 ml/min/kg (mean +/- S.D.) and was identical to that observed after single-dose administration (7.68 +/- 3.19 ml/min/kg).,Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],7.55,75506,DB00186,Lorazepam
,8263762,day-time,The day-time steady-state clearance of free lorazepam measured 7.55 +/- 1.95 ml/min/kg (mean +/- S.D.) and was identical to that observed after single-dose administration (7.68 +/- 3.19 ml/min/kg).,Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],7.68,75507,DB00186,Lorazepam
,8263762,steady-state clearance,The day-time steady-state clearance of free lorazepam measured 7.55 +/- 1.95 ml/min/kg (mean +/- S.D.) and was identical to that observed after single-dose administration (7.68 +/- 3.19 ml/min/kg).,Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],7.55,75508,DB00186,Lorazepam
,8263762,steady-state clearance,The day-time steady-state clearance of free lorazepam measured 7.55 +/- 1.95 ml/min/kg (mean +/- S.D.) and was identical to that observed after single-dose administration (7.68 +/- 3.19 ml/min/kg).,Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],7.68,75509,DB00186,Lorazepam
,8263762,clearances,"Lorazepam clearances were the same during the day as during the night, except in the presence of neomycin and cholestyramine, where night-time clearances were significantly greater (10.16 +/- 3.52 vs. 8.77 +/- 2.43 ml/min/kg, P < or = .05).",Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],10.16,75510,DB00186,Lorazepam
,8263762,clearances,"Lorazepam clearances were the same during the day as during the night, except in the presence of neomycin and cholestyramine, where night-time clearances were significantly greater (10.16 +/- 3.52 vs. 8.77 +/- 2.43 ml/min/kg, P < or = .05).",Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),[ml] / [kg·min],8.77,75511,DB00186,Lorazepam
,8263762,Urinary recoveries,"Urinary recoveries of lorazepam glucuronide, on the other hand, were greater during the day than during the night (114 +/- 11 vs. 77 +/- 15%, P < or = .05) and in all cases were greater than 100% of the administered dose for that interval.",Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),%,114,75512,DB00186,Lorazepam
,8263762,Urinary recoveries,"Urinary recoveries of lorazepam glucuronide, on the other hand, were greater during the day than during the night (114 +/- 11 vs. 77 +/- 15%, P < or = .05) and in all cases were greater than 100% of the administered dose for that interval.",Multiple-dose lorazepam kinetics: shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8263762/),%,77,75513,DB00186,Lorazepam
,2746493,distribution volume,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[l] / [kg],1.89,77010,DB00186,Lorazepam
,2746493,distribution volume,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[l] / [kg],1.81,77011,DB00186,Lorazepam
,2746493,elimination half-life,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),h,11.5,77012,DB00186,Lorazepam
,2746493,elimination half-life,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),h,12.2,77013,DB00186,Lorazepam
,2746493,clearance,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[ml] / [kg·min],2.08,77014,DB00186,Lorazepam
,2746493,clearance,"Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005).",Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2746493/),[ml] / [kg·min],1.88,77015,DB00186,Lorazepam
shorter,22929751,elimination half-life,"In theory, accumulation does not occur with once-daily dosage of benzodiazepines that have an elimination half-life markedly shorter than 24 h, such as oxazepam, temazepam, and lorazepam.",[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929751/),h,24,77548,DB00186,Lorazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],4.8,77646,DB00186,Lorazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],7.2,77647,DB00186,Lorazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],17.9,77648,DB00186,Lorazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,9.3,77649,DB00186,Lorazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,23,77650,DB00186,Lorazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,63,77651,DB00186,Lorazepam
,1974495,Cmax,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[ng] / [ml],11-43,81747,DB00186,Lorazepam
,1974495,Cmax,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[ng] / [ml],11-16,81748,DB00186,Lorazepam
,1974495,AUC0-24,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],66-102,81749,DB00186,Lorazepam
,1974495,AUC0-24,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],54-72,81750,DB00186,Lorazepam
,1974495,AUC0-24,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],83-188,81751,DB00186,Lorazepam
,1974495,AUC0-24,The cirrhotic patients exhibited higher drug plasma levels (Cmax p.o.: 11-43 ng/ml [C] vs. 11-16 ng/ml [N]) and higher AUC0-24 values of the unchanged drug (i.v.: 66-102 ng.h/ml [C] vs. 54-72 ng.h/ml [N]; p.o.: 83-188 ng.h/ml [C] vs. 74-113 ng.h/ml [N]).,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],74-113,81752,DB00186,Lorazepam
,1974495,absolute bioavailability,The absolute bioavailability was increased in the C-group with 57-134% vs. 52-84% [N].,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),%,57-134,81753,DB00186,Lorazepam
,1974495,absolute bioavailability,The absolute bioavailability was increased in the C-group with 57-134% vs. 52-84% [N].,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),%,52-84,81754,DB00186,Lorazepam
,1974495,total plasma clearance,The total plasma clearance of lormetazepam was 3 ml/min/kg in the C-group and 4 ml/min/kg in the N-group and thus within the range known for elderly and young male subjects.,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[ml] / [kg·min],3,81755,DB00186,Lorazepam
,1974495,total plasma clearance,The total plasma clearance of lormetazepam was 3 ml/min/kg in the C-group and 4 ml/min/kg in the N-group and thus within the range known for elderly and young male subjects.,Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[ml] / [kg·min],4,81756,DB00186,Lorazepam
,1974495,AUC-figures,"Conversely to the parent compound, the AUC-figures of its 3-OH-glucuronide were higher in the N-group (346-434 ng.h/ml) than in the C-group (149-371 ng.h/ml).",Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],346-434,81757,DB00186,Lorazepam
,1974495,AUC-figures,"Conversely to the parent compound, the AUC-figures of its 3-OH-glucuronide were higher in the N-group (346-434 ng.h/ml) than in the C-group (149-371 ng.h/ml).",Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974495/),[h·ng] / [ml],149-371,81758,DB00186,Lorazepam
,7880508,Plasma concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.021 to 0.142,82353,DB00186,Lorazepam
,7880508,maximal peak concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.103,82354,DB00186,Lorazepam
,7880508,plasma concentration,The plasma concentration 48 hours after injection varied from 0.026 to 0.074 ng/ml.,Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.026 to 0.074,82355,DB00186,Lorazepam
,24755136,tmax,The exposure to noise significantly prolonged tmax (control vs. noise: 2.0 vs. 3.0 hours) and significantly decreased AUC of lorazepam in the absorption phase.,The effect of experimentally induced sleep disturbance on the pharmacokinetics of lorazepam in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755136/),h,2.0,85471,DB00186,Lorazepam
,24755136,tmax,The exposure to noise significantly prolonged tmax (control vs. noise: 2.0 vs. 3.0 hours) and significantly decreased AUC of lorazepam in the absorption phase.,The effect of experimentally induced sleep disturbance on the pharmacokinetics of lorazepam in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24755136/),h,3.0,85472,DB00186,Lorazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.33,85924,DB00186,Lorazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.45,85925,DB00186,Lorazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,13.1,85926,DB00186,Lorazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,12.2,85927,DB00186,Lorazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.25,85928,DB00186,Lorazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.50,85929,DB00186,Lorazepam
,6132698,free fraction in,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,10.3,85930,DB00186,Lorazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.05,85931,DB00186,Lorazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.19,85932,DB00186,Lorazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.6,85933,DB00186,Lorazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.2,85934,DB00186,Lorazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.60,85935,DB00186,Lorazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],2.03,85936,DB00186,Lorazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.6,85937,DB00186,Lorazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.9,85938,DB00186,Lorazepam
,7452494,peak plasma levels,Absorption of oxazepam was relatively slow with peak plasma levels reached an average of 2 to 3 hr after dosage.,Oxazepam kinetics: effects of age and sex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,2 to 3,89133,DB00186,Lorazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,4.9 to 19.4,89134,DB00186,Lorazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,9.7,89135,DB00186,Lorazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,7.8,89136,DB00186,Lorazepam
,7452494,free fraction,The mean free fraction was 4.3% and did not differ between sexes.,Oxazepam kinetics: effects of age and sex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),%,4.3,89137,DB00186,Lorazepam
,36252,Volumes of distribution,"Volumes of distribution for lorazepam in the elderly group (mean, 0.99 1/kg), were slightly but significantly smaller than in the young group (1.11 1/kg), suggesting less extensive drug distribution in the elderly.",Lorazepam kinetics in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),[1] / [kg],0.99,89725,DB00186,Lorazepam
,36252,Volumes of distribution,"Volumes of distribution for lorazepam in the elderly group (mean, 0.99 1/kg), were slightly but significantly smaller than in the young group (1.11 1/kg), suggesting less extensive drug distribution in the elderly.",Lorazepam kinetics in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),[1] / [kg],1.11,89726,DB00186,Lorazepam
,36252,elimination half-life (t1/2beta),"Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr), but total clearance in the elderly (0.77 ml/min/kg) was 22% less (p less than 0.05) than in the young subjects (0.99 ml/min/kg).",Lorazepam kinetics in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),h,15.9,89727,DB00186,Lorazepam
,36252,elimination half-life (t1/2beta),"Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr), but total clearance in the elderly (0.77 ml/min/kg) was 22% less (p less than 0.05) than in the young subjects (0.99 ml/min/kg).",Lorazepam kinetics in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),h,14.1,89728,DB00186,Lorazepam
,36252,total clearance,"Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr), but total clearance in the elderly (0.77 ml/min/kg) was 22% less (p less than 0.05) than in the young subjects (0.99 ml/min/kg).",Lorazepam kinetics in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),[ml] / [kg·min],0.77,89729,DB00186,Lorazepam
,36252,total clearance,"Values of elimination half-life (t1/2beta) in the elderly (15.9 hr) did not differ significantly from those in the young group (14.1 hr), but total clearance in the elderly (0.77 ml/min/kg) was 22% less (p less than 0.05) than in the young subjects (0.99 ml/min/kg).",Lorazepam kinetics in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),[ml] / [kg·min],0.99,89730,DB00186,Lorazepam
not exceed,36252,absorption half-life (t1/2a),"Peak plasma lorazepam concentrations were always reached within 2.5 hr, and values of absorption half-life (t1/2a) did not exceed 45 min.",Lorazepam kinetics in the elderly. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),min,45,89731,DB00186,Lorazepam
,36252,Absorption,Absorption of IM and oral lorazepam was 80% to 100% complete.,Lorazepam kinetics in the elderly. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),%,80,89732,DB00186,Lorazepam
,36252,Absorption,Absorption of IM and oral lorazepam was 80% to 100% complete.,Lorazepam kinetics in the elderly. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/36252/),%,100,89733,DB00186,Lorazepam
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.6,94730,DB00186,Lorazepam
,6319067,elimination t1/2,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.5,94731,DB00186,Lorazepam
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94732,DB00186,Lorazepam
,6319067,volume of distribution (Vd),"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94733,DB00186,Lorazepam
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.77,94734,DB00186,Lorazepam
,6319067,total clearance,"Kinetic analysis for antipyrine showed no change in elimination t1/2 between trials (mean, 11.6 and 11.5 hr) with no change in volume of distribution (Vd) or total clearance (0.77 and 0.75 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.75,94735,DB00186,Lorazepam
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,32.3,94736,DB00186,Lorazepam
,6319067,t1/2,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,28.9,94737,DB00186,Lorazepam
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94738,DB00186,Lorazepam
,6319067,Vd,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94739,DB00186,Lorazepam
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.42,94740,DB00186,Lorazepam
,6319067,total clearance,Diazepam analysis also showed unchanged t1/2 (32.3 and 28.9 hr) with no change in Vd or total clearance (0.42 and 0.39 ml/min/kg).,"Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],0.39,94741,DB00186,Lorazepam
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.7,94742,DB00186,Lorazepam
,6319067,t1/2,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),h,11.3,94743,DB00186,Lorazepam
,6319067,Vd,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94744,DB00186,Lorazepam
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.52,94745,DB00186,Lorazepam
,6319067,total clearance,"Lorazepam as well had unchanged t1/2 (11.7 and 11.3 hr), Vd, and total clearance (1.52 and 1.65 ml/min/kg).","Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6319067/),[ml] / [kg·min],1.65,94746,DB00186,Lorazepam
,30837282,bioavailability,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),%,114,97385,DB00186,Lorazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],71.5,97386,DB00186,Lorazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],388,97387,DB00186,Lorazepam
,30837282,maximum plasma concentrations,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),[ng] / [ml],355,97388,DB00186,Lorazepam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,5,97389,DB00186,Lorazepam
,30837282,times to peak plasma concentration,"Herein, we report plasma and brain concentrations in rats following coadministration of a hydrophilic diazepam prodrug, avizafone, with the converting enzyme human aminopeptidase B Single doses of avizafone equivalent to diazepam at 0.500, 1.00, and 1.50 mg/kg were administered intranasally, resulting in 77.8% ± 6.0%, 112% ± 10%, and 114% ± 7% bioavailability; maximum plasma concentrations 71.5 ± 9.3, 388 ± 31, and 355 ± 187 ng/ml; and times to peak plasma concentration 5, 8, and 5 minutes for each dose level, respectively.",Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),min,8,97390,DB00186,Lorazepam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.0689,97391,DB00186,Lorazepam
,30837282,first-order absorption rate constants,Enzyme kinetics incorporated into a physiologically based pharmacokinetic model enabled estimation of the first-order absorption rate constants: 0.0689 ± 0.0080 minutes-1 for diazepam and 0.122 ± 0.022 minutes-1 for the intermediate.,Intranasal Coadministration of a Diazepam Prodrug with a Converting Enzyme Results in Rapid Absorption of Diazepam in Rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30837282/),1/[min],0.122,97392,DB00186,Lorazepam
,6126064,apparent comparable half-life,"In 5 male patients undergoing surgery with cardiopulmonary bypass, lorazepam disappeared from the plasma after a single 4 mg intravenous injection with an apparent comparable half-life (10.0 +/- 3.2 min.) to that of the above mentioned surgical patients.",Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126064/),min,10.0,97611,DB00186,Lorazepam
,6126064,apparent half-life,After this peak effect the mean apparent half-life of lorazepam was 15.5 +/- 5.8 hours of indicating no great change in its elimination in comparison with patients operated under local anaesthesia (half-life 12.1 +/- 3.7 hours).,Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126064/),h,15.5,97612,DB00186,Lorazepam
,6126064,half-life,After this peak effect the mean apparent half-life of lorazepam was 15.5 +/- 5.8 hours of indicating no great change in its elimination in comparison with patients operated under local anaesthesia (half-life 12.1 +/- 3.7 hours).,Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126064/),h,12.1,97613,DB00186,Lorazepam
,22216526,Plasma half-life (T1/2),Plasma half-life (T1/2) of unchanged lorazepam in the patient group (11.3 +/- 0.6 h) was not different from that obtained in normals (11.1 +/- 0.9 h).,Biotransformation and excretion of lorazepam in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216526/),h,11.3,98651,DB00186,Lorazepam
,22216526,Plasma half-life (T1/2),Plasma half-life (T1/2) of unchanged lorazepam in the patient group (11.3 +/- 0.6 h) was not different from that obtained in normals (11.1 +/- 0.9 h).,Biotransformation and excretion of lorazepam in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216526/),h,11.1,98652,DB00186,Lorazepam
,22216526,plasma T1/2,The effect of haemodialysis on lorazepam plasma T1/2 was also insignificant (9.4 +/- 1.0 h).,Biotransformation and excretion of lorazepam in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216526/),h,9.4,98653,DB00186,Lorazepam
,22216526,plasma T1/2,The plasma T1/2 of this conjugate in normals was 20.7 +/- 2.1 h.,Biotransformation and excretion of lorazepam in patients with chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216526/),h,20.7,98654,DB00186,Lorazepam
,22216526,plasma protein binding,Roughly 35% of this main metabolite's concentration in plasma was detected in the ultrafiltrate from the coil kidney indicating the dialyzability of this conjugate and that the extent of plasma protein binding of lorazepam-glucuronide in vivo was approximately 65%.,Biotransformation and excretion of lorazepam in patients with chronic renal failure. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216526/),%,65,98655,DB00186,Lorazepam
,2057519,absolute systemic availability,"After oral dosage, absolute systemic availability (relative to intravenous administration) of both lorazepam and clonazepam was incomplete (mean values: 29 and 49%, respectively); however, metabolite levels were also correspondingly lower between oral and intravenous dosages.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),%,29,102045,DB00186,Lorazepam
,2057519,absolute systemic availability,"After oral dosage, absolute systemic availability (relative to intravenous administration) of both lorazepam and clonazepam was incomplete (mean values: 29 and 49%, respectively); however, metabolite levels were also correspondingly lower between oral and intravenous dosages.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),%,49,102046,DB00186,Lorazepam
,2057519,systemic/portal AUC ratios,"First-pass hepatic extraction also occurred for both drugs, with mean systemic/portal AUC ratios of 0.60 for lorazepam and 0.74 for clonazepam.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),,0.60,102047,DB00186,Lorazepam
,2057519,systemic/portal AUC ratios,"First-pass hepatic extraction also occurred for both drugs, with mean systemic/portal AUC ratios of 0.60 for lorazepam and 0.74 for clonazepam.",Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2057519/),,0.74,102048,DB00186,Lorazepam
,10966246,volume of distribution,"Mean kinetic values for lorazepam were as follows: volume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min.",Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966246/),l,126,110241,DB00186,Lorazepam
,10966246,elimination half-life,"Mean kinetic values for lorazepam were as follows: volume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min.",Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966246/),h,13.8,110242,DB00186,Lorazepam
,10966246,clearance,"Mean kinetic values for lorazepam were as follows: volume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min.",Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966246/),[ml] / [min],109,110243,DB00186,Lorazepam
,10966246,50% effective concentration,"The analysis yielded the following mean estimates: maximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins.",Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966246/),[ng] / [ml],13.1,110244,DB00186,Lorazepam
,10966246,half-life,"The analysis yielded the following mean estimates: maximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins.",Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966246/),min,8.8,110245,DB00186,Lorazepam
,22396304,T (max),"Coating the drug with the vinyl polymer, MP1 (9.9 ± 0.5 μm with 38.8 ± 14.0%, w/w lorazepam) and MP2 (10.7 ± 0.1 μm with 47.0 ± 1.0%, w/w lorazepam), allowed rapid systemic absorption (MP1, T (max) 14.2 ± 4.9 min; MP2, T (max) 9.3 ± 3.8 min) in rabbits and modified the PK profiles in a manner that suggested successful nasal retention.",Pharmacokinetic evaluation of intranasally administered vinyl polymer-coated lorazepam microparticles in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396304/),min,14.2,112209,DB00186,Lorazepam
,22396304,T (max),"Coating the drug with the vinyl polymer, MP1 (9.9 ± 0.5 μm with 38.8 ± 14.0%, w/w lorazepam) and MP2 (10.7 ± 0.1 μm with 47.0 ± 1.0%, w/w lorazepam), allowed rapid systemic absorption (MP1, T (max) 14.2 ± 4.9 min; MP2, T (max) 9.3 ± 3.8 min) in rabbits and modified the PK profiles in a manner that suggested successful nasal retention.",Pharmacokinetic evaluation of intranasally administered vinyl polymer-coated lorazepam microparticles in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22396304/),min,9.3,112210,DB00186,Lorazepam
,25464106,flow rate,"Separation of analytes was performed with a Hypersil C18 column and a mobile phase with acetonitrile and 0.1% formic acid (60/40, v/v) under isocratic conditions at a flow rate of 280μl/min.","Simultaneous detection of ketamine, lorazepam, midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464106/),[μl] / [min],280,112299,DB00186,Lorazepam
,16243469,t(1/2a),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),h,3.5,116633,DB00186,Lorazepam
,16243469,K(a),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),1/[ngh],0.198,116634,DB00186,Lorazepam
,16243469,t(1/2),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),h,11.5,116635,DB00186,Lorazepam
,16243469,beta,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),1/[h],0.060,116636,DB00186,Lorazepam
,16243469,AUC(0-infinity),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),[ngh] / [ml],192.1,116637,DB00186,Lorazepam
,16243469,CLt/f,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),[ml] / [minkg],2.41,116638,DB00186,Lorazepam
,16243469,Vd/f,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),l,173.5,116639,DB00186,Lorazepam
,16243469,Fel,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),%,0.41,116640,DB00186,Lorazepam
,16243469,Cl(R),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),[ml] / [minkg],0.0099,116641,DB00186,Lorazepam
,16243469,t(1/2f),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),h,1.2,116642,DB00186,Lorazepam
,16243469,K(f),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),1/[h],0.578,116643,DB00186,Lorazepam
,16243469,t(1/2),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),h,16.6,116644,DB00186,Lorazepam
,16243469,beta,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),1/[h],0.042,116645,DB00186,Lorazepam
,16243469,AUC(0-infinity),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),[ngh] / [ml],207.6,116646,DB00186,Lorazepam
,16243469,Fel,"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),%,51.80,116647,DB00186,Lorazepam
,16243469,Cl(R),"The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg).",Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16243469/),[ml] / [minkg],98.32,116648,DB00186,Lorazepam
,1934861,clearance,"Antipyrine clearance was increased significantly from baseline (0.50 +/- 0.31 ml/min/kg) on study days 4, 7, and 14 (p less than 0.0001).",Effect of neurotrauma on hepatic drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934861/),[ml] / [kg·min],0.50,117567,DB00186,Lorazepam
,1934861,clearance,A significant increase was also observed in lorazepam clearance on study day 14 relative to baseline (1.39 +/- 0.56 ml/min/kg) (p less than 0.005).,Effect of neurotrauma on hepatic drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1934861/),[ml] / [kg·min],1.39,117568,DB00186,Lorazepam
,1881994,elimination half-life,"Mean kinetic values for the two drugs, respectively, were: elimination half-life, 5.7 and 1.7 h; oral clearance, 5.5 and 40.2 ml/min/kg.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),h,5.7,120655,DB00186,Lorazepam
,1881994,elimination half-life,"Mean kinetic values for the two drugs, respectively, were: elimination half-life, 5.7 and 1.7 h; oral clearance, 5.5 and 40.2 ml/min/kg.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),h,1.7,120656,DB00186,Lorazepam
,1881994,oral clearance,"Mean kinetic values for the two drugs, respectively, were: elimination half-life, 5.7 and 1.7 h; oral clearance, 5.5 and 40.2 ml/min/kg.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),[ml] / [kg·min],5.5,120657,DB00186,Lorazepam
,1881994,oral clearance,"Mean kinetic values for the two drugs, respectively, were: elimination half-life, 5.7 and 1.7 h; oral clearance, 5.5 and 40.2 ml/min/kg.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),[ml] / [kg·min],40.2,120658,DB00186,Lorazepam
,1881994,elimination half-life,"Mean values of elimination half-life in humans (11.5 and 12.4 h, for alprazolam and lorazepam, respectively) were substantially longer than corresponding values in the primate animal model, and human values of clearance (0.85 and 1.40 ml/min/kg) likewise were much lower.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),h,11.5,120659,DB00186,Lorazepam
,1881994,elimination half-life,"Mean values of elimination half-life in humans (11.5 and 12.4 h, for alprazolam and lorazepam, respectively) were substantially longer than corresponding values in the primate animal model, and human values of clearance (0.85 and 1.40 ml/min/kg) likewise were much lower.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),h,12.4,120660,DB00186,Lorazepam
,1881994,clearance,"Mean values of elimination half-life in humans (11.5 and 12.4 h, for alprazolam and lorazepam, respectively) were substantially longer than corresponding values in the primate animal model, and human values of clearance (0.85 and 1.40 ml/min/kg) likewise were much lower.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),[ml] / [kg·min],0.85,120661,DB00186,Lorazepam
,1881994,clearance,"Mean values of elimination half-life in humans (11.5 and 12.4 h, for alprazolam and lorazepam, respectively) were substantially longer than corresponding values in the primate animal model, and human values of clearance (0.85 and 1.40 ml/min/kg) likewise were much lower.",Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881994/),[ml] / [kg·min],1.40,120662,DB00186,Lorazepam
,17063976,concentration,"The median concentration was 59 ng/ml, interquartile range 23 - 93 ng/ml, range 0 - 1,072 ng/ml.","Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063976/),[ng] / [ml],59,125160,DB00186,Lorazepam
,17063976,Clearance,Clearance was preserved at 92 +/- 71 ml/min.,"Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063976/),[ml] / [min],92,125161,DB00186,Lorazepam
,17063976,concentrations,"CIVS administration was associated with higher concentrations (629 +/- 36 versus 49 +/- 15 ng/ml, p-value < 0.001) and deeper sedation by both SAS and BIS.","Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063976/),[ng] / [ml],629,125162,DB00186,Lorazepam
,17063976,concentrations,"CIVS administration was associated with higher concentrations (629 +/- 36 versus 49 +/- 15 ng/ml, p-value < 0.001) and deeper sedation by both SAS and BIS.","Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063976/),[ng] / [ml],49,125163,DB00186,Lorazepam
,3066417,elimination half-life,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),h,15.6,126921,DB00186,Lorazepam
,3066417,elimination half-life,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),h,11.7,126922,DB00186,Lorazepam
,3066417,maximal concentration,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),[ng] / [ml],40.8,126923,DB00186,Lorazepam
,3066417,maximal concentration,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),[ng] / [ml],42.2,126924,DB00186,Lorazepam
,3066417,time to reach maximal concentration,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),h,1.2,126925,DB00186,Lorazepam
,3066417,time to reach maximal concentration,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),h,1.4,126926,DB00186,Lorazepam
,3066417,area under the curve,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),[ng] / [hml],310.6,126927,DB00186,Lorazepam
,3066417,area under the curve,"The main pharmacokinetic parameters for the oral and sublingual tablets were, respectively: elimination half-life 15.6h and 11.7h; maximal concentration 40.8 ng ml-1 and 42.2 ng ml-1; time to reach maximal concentration 1.2h and 1.4h; corrected area under the curve 310.6 ng hml-1 and 313.6 ng hml-1.",Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3066417/),[ng] / [hml],313.6,126928,DB00186,Lorazepam
,2743706,Urinary recoveries,"Urinary recoveries also differed (71.6% and 50.4%, oral versus intravenous).",Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743706/),%,71.6,126934,DB00186,Lorazepam
,2743706,Urinary recoveries,"Urinary recoveries also differed (71.6% and 50.4%, oral versus intravenous).",Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743706/),%,50.4,126935,DB00186,Lorazepam
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"76,600",127603,DB00186,Lorazepam
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],"90,600",127604,DB00186,Lorazepam
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],525,127605,DB00186,Lorazepam
,10435726,area under the curve (AUC),"Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group.",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),[μg] / [min·ml],648,127606,DB00186,Lorazepam
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,544,127607,DB00186,Lorazepam
,10435726,AUC,"The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43).",Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435726/),,677,127608,DB00186,Lorazepam
,1973917,peak plasma levels,The disposition of lormetazepam in plasma was characterized by peak plasma levels of 14-60 ng/ml after 20-40 min.,Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1973917/),[ng] / [ml],14-60,131072,DB00186,Lorazepam
,1973917,oral clearance,The areas and the plasma levels vs time curves of lormetazepam and its glucuronide were not statistically different and the oral clearance of lormetazepam was similar in both parts of the study (median 3.1 and 3.6 ml/min/kg).,Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1973917/),[ml] / [kg·min],3.1,131073,DB00186,Lorazepam
,1973917,oral clearance,The areas and the plasma levels vs time curves of lormetazepam and its glucuronide were not statistically different and the oral clearance of lormetazepam was similar in both parts of the study (median 3.1 and 3.6 ml/min/kg).,Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1973917/),[ml] / [kg·min],3.6,131074,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],56.5,135031,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],25.9,135032,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],892.5,135033,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],256.5,135034,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],27.2,135035,DB00186,Lorazepam
,2246703,plasma clearance,Patients with CF had a significantly greater plasma clearance of lorazepam (56.5 +/- 5.2 vs 25.9 +/- 1.9 ml/min/m2) and ICG (892.5 +/- 176.4 vs 256.5 +/- 41.7 ml/min/m2) but not of antipyrine (27.2 +/- 3.8 vs 20.7 +/- 2.0 ml/min/m2) in comparison with control subjects.,Enhanced hepatic drug clearance in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2246703/),[ml] / [m2·min],20.7,135036,DB00186,Lorazepam
,10470750,maximum dose,The maximum dose allowed for each drug was 60 mg/hr for midazolam and 4 mg/hr for lorazepam.,Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470750/),,60,135664,DB00186,Lorazepam
,10470750,maximum dose,The maximum dose allowed for each drug was 60 mg/hr for midazolam and 4 mg/hr for lorazepam.,Continuous infusion of lorazepam versus medazolam in patients in the intensive care unit: sedation with lorazepam is easier to manage and is more cost-effective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470750/),,4,135665,DB00186,Lorazepam
,17718192,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 207 ng/ml (reference), 198 ng/ml (A), 166 ng/ml (B) and 169 ng/ml (C) were achieved.",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[ng] / [ml],207,135964,DB00186,Lorazepam
,17718192,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 207 ng/ml (reference), 198 ng/ml (A), 166 ng/ml (B) and 169 ng/ml (C) were achieved.",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[ng] / [ml],198,135965,DB00186,Lorazepam
,17718192,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 207 ng/ml (reference), 198 ng/ml (A), 166 ng/ml (B) and 169 ng/ml (C) were achieved.",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[ng] / [ml],166,135966,DB00186,Lorazepam
,17718192,Maximum plasma concentrations (Cmax),"Maximum plasma concentrations (Cmax), of 207 ng/ml (reference), 198 ng/ml (A), 166 ng/ml (B) and 169 ng/ml (C) were achieved.",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[ng] / [ml],169,135967,DB00186,Lorazepam
,17718192,Tmax,"Lorazepam appeared in the plasma at 0.66 h (Tmax) for all formulations, probably because the disintegration step was bypassed due to the pulverization of the administered doses.",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),h,0.66,135968,DB00186,Lorazepam
,17718192,AUC(0-t),"The obtained AUC(0-t) values were 556.57 ng h/ml (reference), 554.70 ng h/ml (A), 493.08 ng h/ml (B), and 487.88 ng h/ml (C).",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[h·ng] / [ml],556.57,135969,DB00186,Lorazepam
,17718192,AUC(0-t),"The obtained AUC(0-t) values were 556.57 ng h/ml (reference), 554.70 ng h/ml (A), 493.08 ng h/ml (B), and 487.88 ng h/ml (C).",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[h·ng] / [ml],554.70,135970,DB00186,Lorazepam
,17718192,AUC(0-t),"The obtained AUC(0-t) values were 556.57 ng h/ml (reference), 554.70 ng h/ml (A), 493.08 ng h/ml (B), and 487.88 ng h/ml (C).",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[h·ng] / [ml],493.08,135971,DB00186,Lorazepam
,17718192,AUC(0-t),"The obtained AUC(0-t) values were 556.57 ng h/ml (reference), 554.70 ng h/ml (A), 493.08 ng h/ml (B), and 487.88 ng h/ml (C).",Technological evaluation and equivalence assessment of lorazepam tablets in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17718192/),[h·ng] / [ml],487.88,135972,DB00186,Lorazepam
,8112251,formation,"In the IPRL studies, VPA also significantly decreased formation of LZP glucuronide (from 0.72 +/- 0.14 to 0.22 +/- 0.15 ml/h/kg, p < 0.05), indicating that IPRL is a useful tool for evaluation of the effect of VPA on drugs eliminated by glucuronide conjugation.",Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8112251/),m,0.,136538,DB00186,Lorazepam
,11697755,bioavailability,Lorazepam was well absorbed following intranasal administration with a mean (%CV) bioavailability of 77.7(11.1).,"Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697755/),,77.7,136931,DB00186,Lorazepam
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),min,30-40,140482,DB00186,Lorazepam
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),h,8-10,140483,DB00186,Lorazepam
,12404702,bioavailability,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,48,142126,DB00186,Lorazepam
,12404702,protein binding,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,17,142127,DB00186,Lorazepam
,12404702,elimination half-life,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),h,12,142128,DB00186,Lorazepam
,20218012,peak plasma lorazepam concentrations,"Following single 4-mg oral doses, peak plasma lorazepam concentrations ranging from 40 to 70 ng/ml were reached within 3 hr of the dose.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ng] / [ml],40 to 70,156754,DB00186,Lorazepam
,20218012,absorption half-life,"Values of absorption half-life averaged 25 min (range 10.3-42.7 min), and elimination half-life (t1/2 beta) averaged 14.2 hr (range 8.4-23.9 hr).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),min,25,156755,DB00186,Lorazepam
,20218012,elimination half-life (t1/2 beta),"Values of absorption half-life averaged 25 min (range 10.3-42.7 min), and elimination half-life (t1/2 beta) averaged 14.2 hr (range 8.4-23.9 hr).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,14.2,156756,DB00186,Lorazepam
,20218012,accumulation half-life,"Values of accumulation half-life (mean 21.1 hr) were slightly longer than t1/2beta, and the two were not well correlated.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,21.1,156757,DB00186,Lorazepam
,20218012,accumulation ratios,"Observed accumulation ratios (mean 1.88) were very close to those predicted from the single-dose study (mean 1.77), but the correlation between the two (r = 0.51) was not significant in the small sample size.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),,1.88,156758,DB00186,Lorazepam
,20218012,accumulation ratios,"Observed accumulation ratios (mean 1.88) were very close to those predicted from the single-dose study (mean 1.77), but the correlation between the two (r = 0.51) was not significant in the small sample size.",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),,1.77,156759,DB00186,Lorazepam
,20218012,"""Washout"" half-life","""Washout"" half-life values (mean 14.9 hr) were highly correlated with t1/2beta (r = 0.92).",Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),h,14.9,156760,DB00186,Lorazepam
,20218012,Clearance,Clearance of a single intravenous dose of antipyrine determined prior to the multiple-dose lorazepam study (mean 0.86 ml/min/kg) was essentially identical to that determined after the study (mean 0.87 ml/ min/kg).,Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ml] / [kg·min],0.86,156761,DB00186,Lorazepam
,20218012,Clearance,Clearance of a single intravenous dose of antipyrine determined prior to the multiple-dose lorazepam study (mean 0.86 ml/min/kg) was essentially identical to that determined after the study (mean 0.87 ml/ min/kg).,Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20218012/),[ml] / [kg·min],0.87,156762,DB00186,Lorazepam
,6132630,elimination half-lives,"Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-lives for the sublingual and oral doses are estimated to be 11 and 8 h, respectively, while the corresponding absorption half-lives are 15 and 55 min; this confirms earlier reports that the sublingual formulation is more rapidly absorbed.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),h,11,157048,DB00186,Lorazepam
,6132630,elimination half-lives,"Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-lives for the sublingual and oral doses are estimated to be 11 and 8 h, respectively, while the corresponding absorption half-lives are 15 and 55 min; this confirms earlier reports that the sublingual formulation is more rapidly absorbed.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),h,8,157049,DB00186,Lorazepam
,6132630,absorption half-lives,"Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-lives for the sublingual and oral doses are estimated to be 11 and 8 h, respectively, while the corresponding absorption half-lives are 15 and 55 min; this confirms earlier reports that the sublingual formulation is more rapidly absorbed.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),min,15,157050,DB00186,Lorazepam
,6132630,absorption half-lives,"Fitting a multi-dose equation based on a one-compartment model to the observed data, the average elimination half-lives for the sublingual and oral doses are estimated to be 11 and 8 h, respectively, while the corresponding absorption half-lives are 15 and 55 min; this confirms earlier reports that the sublingual formulation is more rapidly absorbed.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),min,55,157051,DB00186,Lorazepam
,6132630,time to steady-state,"The observed time to steady-state for both formulations was approximately 3 days, which agrees well with that predicted from previous single dosing studies.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),d,3,157052,DB00186,Lorazepam
,6132630,steady-state minimum plasma concentration,"Although the sublingual formulation yields a higher average steady-state minimum plasma concentration than the oral formulation (41.6 versus 38.1 ng ml-1), the maximum lorazepam concentration achieved during steady state was approximately 83 ng ml-1 for both formulations.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),[ng] / [ml],41.6,157053,DB00186,Lorazepam
,6132630,steady-state minimum plasma concentration,"Although the sublingual formulation yields a higher average steady-state minimum plasma concentration than the oral formulation (41.6 versus 38.1 ng ml-1), the maximum lorazepam concentration achieved during steady state was approximately 83 ng ml-1 for both formulations.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),[ng] / [ml],38.1,157054,DB00186,Lorazepam
,6132630,maximum lorazepam concentration achieved during steady state,"Although the sublingual formulation yields a higher average steady-state minimum plasma concentration than the oral formulation (41.6 versus 38.1 ng ml-1), the maximum lorazepam concentration achieved during steady state was approximately 83 ng ml-1 for both formulations.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),[ng] / [ml],83,157055,DB00186,Lorazepam
,6132630,steady-state plasma concentration,"The average steady-state plasma concentration is estimated to be 63 ng ml-1, independent of the formulation used.","Pharmacokinetics of two lorazepam formulations, oral and sublingual, after multiple doses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132630/),[ng] / [ml],63,157056,DB00186,Lorazepam
,14508316,V1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,14.4,157827,DB00186,Lorazepam
,14508316,V2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,36.4,157828,DB00186,Lorazepam
,14508316,V3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,169,157829,DB00186,Lorazepam
,14508316,Cl1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],0.82,157830,DB00186,Lorazepam
,14508316,Cl2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],2.31,157831,DB00186,Lorazepam
,14508316,Cl3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],1.35,157832,DB00186,Lorazepam
,11192474,half-life,"The plasma concentration-time profile following oral administration is best described by a 1-compartment model, and the mean half-life (approximately 12 hours) is consistent with the recommendation to administer the drug twice daily.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),h,12,158838,DB00186,Lorazepam
,11192474,absolute bioavailability,"The absolute bioavailability is 94.5%, and maximal concentrations are generally achieved within 2 to 4 hours.","Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11192474/),%,94.5,158839,DB00186,Lorazepam
,16085142,detection limit,"A detection limit of 0.10 ng/ml for lorazepam was achieved, and inter- and intra-run precisions of better than 4.4% (R.S.D.) were observed.",A fast and sensitive liquid chromatographic-tandem mass spectrometric method for assay of lorazepam and application to pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085142/),[ng] / [ml],0.10,159137,DB00186,Lorazepam
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00186,Lorazepam
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00186,Lorazepam
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00186,Lorazepam
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00186,Lorazepam
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00186,Lorazepam
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00186,Lorazepam
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00186,Lorazepam
>,15532067,m/z,"The acquisition was performed in the multiple reaction monitoring mode, monitoring the transitions: m/z 316 > 182 for bromazepam and m/z 321 > 275 for lorazepam.",Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15532067/),,316,165619,DB00186,Lorazepam
>,15532067,m/z,"The acquisition was performed in the multiple reaction monitoring mode, monitoring the transitions: m/z 316 > 182 for bromazepam and m/z 321 > 275 for lorazepam.",Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15532067/),,182,165620,DB00186,Lorazepam
>,15532067,m/z 321,"The acquisition was performed in the multiple reaction monitoring mode, monitoring the transitions: m/z 316 > 182 for bromazepam and m/z 321 > 275 for lorazepam.",Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15532067/),,275,165621,DB00186,Lorazepam
,15532067,run time,"The method was linear over the studied range (1-100 ng ml(-1)), with r(2) > 0.98, and the run time was 2.5 min.",Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15532067/),min,2.5,165622,DB00186,Lorazepam
,15532067,recovery,"The mean recovery was 73.7%, ranging from 64.5 to 79.7%.",Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15532067/),%,73.7,165623,DB00186,Lorazepam
,7589050,cycling-interrupted clearance,"However, patients on beef/pork insulin exhibited a greater than normal increase on this interupting regimen (125%), and had a significantly greater neomycin/cholestyramine cycling-interrupted clearance of lorazepam than either normal controls or patients on human insulin (15.4 vs. 6.96 and 7.87 ml.min-1.kg-1).",Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589050/),[ml] / [kg·min],15.4,166533,DB00186,Lorazepam
,7589050,cycling-interrupted clearance,"However, patients on beef/pork insulin exhibited a greater than normal increase on this interupting regimen (125%), and had a significantly greater neomycin/cholestyramine cycling-interrupted clearance of lorazepam than either normal controls or patients on human insulin (15.4 vs. 6.96 and 7.87 ml.min-1.kg-1).",Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589050/),[ml] / [kg·min],6.96,166534,DB00186,Lorazepam
,7589050,cycling-interrupted clearance,"However, patients on beef/pork insulin exhibited a greater than normal increase on this interupting regimen (125%), and had a significantly greater neomycin/cholestyramine cycling-interrupted clearance of lorazepam than either normal controls or patients on human insulin (15.4 vs. 6.96 and 7.87 ml.min-1.kg-1).",Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589050/),[ml] / [kg·min],7.87,166535,DB00186,Lorazepam
,3345616,total volume of distribution,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),[l] / [kg],2.66,167606,DB00186,Lorazepam
,3345616,total volume of distribution,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),[l] / [kg],1.39,167607,DB00186,Lorazepam
,3345616,clearance,The burned patients had increases in total volume of distribution (2.66 +/- 0.55 vs. 1.39 +/- 0.1 L/kg; P less than 0.02) and clearance (4.28 +/- 1.20 vs.,Lorazepam conjugation is unimpaired in burn trauma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),,4.28,167608,DB00186,Lorazepam
,3345616,half-life,"1.16 +/- 0.1 ml/min/kg; P less than 0.01), whereas the half-life was significantly reduced in the burned group (9.6 +/- 1.3 vs. 13.9 +/- 0.9 hours; P less than 0.025).",Lorazepam conjugation is unimpaired in burn trauma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),h,9.6,167609,DB00186,Lorazepam
,3345616,half-life,"1.16 +/- 0.1 ml/min/kg; P less than 0.01), whereas the half-life was significantly reduced in the burned group (9.6 +/- 1.3 vs. 13.9 +/- 0.9 hours; P less than 0.025).",Lorazepam conjugation is unimpaired in burn trauma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3345616/),h,13.9,167610,DB00186,Lorazepam
,15197439,plasma concentrations,"Using a dose of 3-5 microg/kg every 8 h, plasma concentrations appeared to plateau at approximately 41 h giving a mean value of 1.38 ng/ml (95% confidence interval 1.0-1.8).",Use of oral clonidine for sedation in ventilated paediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197439/),,1,168584,DB00186,Lorazepam
,6108174,absorption half-lifes (t1/2s),Oral doses were completely absorbed with widely varying absorption half-lifes (t1/2s) amounting to an average of 0.67 +/- 0.53 hr.,Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),h,0.67,168815,DB00186,Lorazepam
,6108174,Total clearance,Total clearance was in the range of 200 ml/min.,Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),[ml] / [min],200,168816,DB00186,Lorazepam
,6108174,terminal phase t1/2,"In younger subjects, the terminal phase t1/2 was about 10 hr.",Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),h,10,168817,DB00186,Lorazepam
,6108174,t1/2,"Thereafter, the level fell in one (elimination) phase, with a t1/2 of 12 hr in young subjects and with a significantly (p < 0.05) different t1/2 of about 20 hr in the elderly.",Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),h,12,168818,DB00186,Lorazepam
,6108174,t1/2,"Thereafter, the level fell in one (elimination) phase, with a t1/2 of 12 hr in young subjects and with a significantly (p < 0.05) different t1/2 of about 20 hr in the elderly.",Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),h,20,168819,DB00186,Lorazepam
,6108174,Renal clearance,Renal clearance was calculated as about 30 to 40 ml and did not show an age-dependent difference.,Kinetics and biotransformation of lormetazepam. Radioimmunologic determinations in plasma and urine of young and elderly subjects: first-pass effect. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6108174/),ml,30 to 40,168820,DB00186,Lorazepam
,19508,apparent elimination half-life,"Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min.",Clinical pharmacokinetics of lorazepam. Intravenous injection. Preliminary results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19508/),h,13.2,170750,DB00186,Lorazepam
,19508,volume of distribution,"Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min.",Clinical pharmacokinetics of lorazepam. Intravenous injection. Preliminary results. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19508/),[l] / [kg],0.84,170751,DB00186,Lorazepam
,19508,total clearance,"Mean pharmacokinetic parameters for lorazepam were: apparent elimination half-life, 13.2 hours; volume of distribution, 0.84 liter/kg; total clearance, 55.3 ml/min.",Clinical pharmacokinetics of lorazepam. Intravenous injection. Preliminary results. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19508/),[ml] / [min],55.3,170752,DB00186,Lorazepam
,6124982,elimination half-life,Applying an open two-compartment body model the drug was excreted with an elimination half-life of 10.3 hours.,Relationship between EEG dynamics and pharmacokinetics of the benzodiazepine lormetazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124982/),h,10.3,173841,DB00186,Lorazepam
,6103631,biological half-life (t 1/2 beta),Lorazepam showed distinct linear two-compartment characteristics with a mean biological half-life (t 1/2 beta) of only 73.7 min.,Disposition pharmacokinetics of lorazepam in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),min,73.7,176171,DB00186,Lorazepam
,6103631,half-life of the alpha phase of distribution,The mean half-life of the alpha phase of distribution was 18.4 min.,Disposition pharmacokinetics of lorazepam in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),min,18.4,176172,DB00186,Lorazepam
,6103631,apparent steady state volume of distribution,"The mean apparent steady state volume of distribution was 1.64 1 kg-1 +/- 0.27 S.D., Vc-mean was 1.11 1 kg-1 +/- 0.24 S.D. and Vdarea 2.26 1 kg-1 +/- 0.16 S.D.",Disposition pharmacokinetics of lorazepam in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),[1] / [kg],1.64,176173,DB00186,Lorazepam
,6103631,Vc-mean,"The mean apparent steady state volume of distribution was 1.64 1 kg-1 +/- 0.27 S.D., Vc-mean was 1.11 1 kg-1 +/- 0.24 S.D. and Vdarea 2.26 1 kg-1 +/- 0.16 S.D.",Disposition pharmacokinetics of lorazepam in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),[1] / [kg],1.11,176174,DB00186,Lorazepam
,6103631,Vdarea,"The mean apparent steady state volume of distribution was 1.64 1 kg-1 +/- 0.27 S.D., Vc-mean was 1.11 1 kg-1 +/- 0.24 S.D. and Vdarea 2.26 1 kg-1 +/- 0.16 S.D.",Disposition pharmacokinetics of lorazepam in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),[1] / [kg],2.26,176175,DB00186,Lorazepam
,6103631,apparent volume of the peripheral compartment,The calculated apparent volume of the peripheral compartment amounted to 0.53 1 kg-1 +/- 0.28 S.D.,Disposition pharmacokinetics of lorazepam in the rabbit. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6103631/),[1] / [kg],0.53,176176,DB00186,Lorazepam
,20376593,Peak serum topiramate level,"Peak serum topiramate level was 356.6 microg/ml (reference range, 5-20 microg/ml).",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),[μg] / [ml],356.6,179957,DB00186,Lorazepam
,20376593,Serum half-life,"Serum half-life, which has not been studied after overdose, was 16 h.",Clinical effects and toxicokinetic evaluation following massive topiramate ingestion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20376593/),h,16,179958,DB00186,Lorazepam
,6121043,elimination half-life (t 1/2 beta),"After intravenous lorazepam, mean (+/- SE) values were: elimination half-life (t 1/2 beta), 12.9 (+/- 0.8) hr; volume of distribution, 1.3 (+/- 0.07) liters/kg; total clearance, 1.21 (+/- 0.1) ml/min/kg.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),h,12.9,182869,DB00186,Lorazepam
,6121043,volume of distribution,"After intravenous lorazepam, mean (+/- SE) values were: elimination half-life (t 1/2 beta), 12.9 (+/- 0.8) hr; volume of distribution, 1.3 (+/- 0.07) liters/kg; total clearance, 1.21 (+/- 0.1) ml/min/kg.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),[l] / [kg],1.3,182870,DB00186,Lorazepam
,6121043,total clearance,"After intravenous lorazepam, mean (+/- SE) values were: elimination half-life (t 1/2 beta), 12.9 (+/- 0.8) hr; volume of distribution, 1.3 (+/- 0.07) liters/kg; total clearance, 1.21 (+/- 0.1) ml/min/kg.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),[ml] / [kg·min],1.21,182871,DB00186,Lorazepam
,6121043,absorption half-life,"Peak plasma levels were reached at 1.15 hr after dosage, with absorption half-life averaging 14.2 (+/- 4.7) min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),min,14.2,182872,DB00186,Lorazepam
,6121043,Times of peak concentration,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),h,2.37,182873,DB00186,Lorazepam
,6121043,Times of peak concentration,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),h,2.35,182874,DB00186,Lorazepam
,6121043,Times of peak concentration,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),h,2.25,182875,DB00186,Lorazepam
,6121043,absorption half-life,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),min,32.5,182876,DB00186,Lorazepam
,6121043,absorption half-life,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),min,28.5,182877,DB00186,Lorazepam
,6121043,absorption half-life,"Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),min,28.7,182878,DB00186,Lorazepam
,6121043,Absolute systemic availability,"Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),%,95.9,182879,DB00186,Lorazepam
,6121043,Absolute systemic availability,"Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),%,99.8,182880,DB00186,Lorazepam
,6121043,Absolute systemic availability,"Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),%,94.1,182881,DB00186,Lorazepam
,6121043,Absolute systemic availability,"Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%.","Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121043/),%,98.2,182882,DB00186,Lorazepam
,6147846,peak concentrations,"After absorption, plasma lormetazepam levels rapidly reached mean (+/- s.d.) peak concentrations of 4.9 +/- 0.9 ng/ml and 5.2 +/- 1.7 ng/ml for the sublingual and oral routes, respectively, there being no significant difference (p greater than 0.05) between these values.",Lormetazepam--plasma concentrations in volunteers following sublingual and oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147846/),[ng] / [ml],4.9,186263,DB00186,Lorazepam
,6147846,peak concentrations,"After absorption, plasma lormetazepam levels rapidly reached mean (+/- s.d.) peak concentrations of 4.9 +/- 0.9 ng/ml and 5.2 +/- 1.7 ng/ml for the sublingual and oral routes, respectively, there being no significant difference (p greater than 0.05) between these values.",Lormetazepam--plasma concentrations in volunteers following sublingual and oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147846/),[ng] / [ml],5.2,186264,DB00186,Lorazepam
,6147846,terminal half-lives,"Elimination of lormetazepam followed a similar pattern following sublingual and oral dosing, the mean terminal half-lives being 13.0 h and 13.8 h, respectively.",Lormetazepam--plasma concentrations in volunteers following sublingual and oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147846/),h,13.0,186265,DB00186,Lorazepam
,6147846,terminal half-lives,"Elimination of lormetazepam followed a similar pattern following sublingual and oral dosing, the mean terminal half-lives being 13.0 h and 13.8 h, respectively.",Lormetazepam--plasma concentrations in volunteers following sublingual and oral dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147846/),h,13.8,186266,DB00186,Lorazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],1.56,187947,DB00186,Lorazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],5.40,187948,DB00186,Lorazepam
,24604775,elimination half-life,"Based on this study, diclazepam has an approximate elimination half-life of 42 h and is metabolized into the pharmacologically active benzodiazepines delorazepam, lorazepam, and lormetazepam which can be detected in urine for 6, 19, and 11 days, respectively, when applying the presented LC-MS/MS method.",Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24604775/),h,42,191172,DB00186,Lorazepam
,43806,half-life of elimination,After both treatments the terminal half-life of total radioactivity and lormetazepam glucuronide in plasma corresponded to the half-life of elimination in urine of about 13 hours.,"The pharmacokinetics and biotransformation of the new benzodiazepine lormetazepam in humans. I. Absorption, distribution, elimination and metabolism of lormetazepam-5-14C. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43806/),h,13,191186,DB00186,Lorazepam
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00186,Lorazepam
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00186,Lorazepam
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00186,Lorazepam
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00186,Lorazepam
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00186,Lorazepam
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00186,Lorazepam
,18543419,infusion rate,"In this cohort, the median lorazepam infusion rate was 2.1 mg/h (0.5-18).",A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18543419/),[mg] / [h],2.1,200451,DB00186,Lorazepam
,18543419,infusion rate,"When propylene glycol concentrations were >25 mg/dL, the median lorazepam infusion rate before sample collection was higher, 6.4 (1.9-11.3) versus 2.0 (0.5-7.4) mg/h (P =.0003).",A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18543419/),[mg] / [h],6.4,200452,DB00186,Lorazepam
,18543419,infusion rate,"When propylene glycol concentrations were >25 mg/dL, the median lorazepam infusion rate before sample collection was higher, 6.4 (1.9-11.3) versus 2.0 (0.5-7.4) mg/h (P =.0003).",A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18543419/),[mg] / [h],2.0,200453,DB00186,Lorazepam
,13960,apparent absorption half-life,Mean pharmacokinetic pamrameters for unchanged lorazepam were: apparent absorption half-life: 21.2 min; elimination half-life: 13.6 hr; volume of distribution: 0.9 L/kg; total clearance: 58.2 ml/min.,Clinical pharmacokinetics of lorazepam. Intramuscular injection. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13960/),min,21.2,203364,DB00186,Lorazepam
,13960,elimination half-life,Mean pharmacokinetic pamrameters for unchanged lorazepam were: apparent absorption half-life: 21.2 min; elimination half-life: 13.6 hr; volume of distribution: 0.9 L/kg; total clearance: 58.2 ml/min.,Clinical pharmacokinetics of lorazepam. Intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13960/),h,13.6,203365,DB00186,Lorazepam
,13960,volume of distribution,Mean pharmacokinetic pamrameters for unchanged lorazepam were: apparent absorption half-life: 21.2 min; elimination half-life: 13.6 hr; volume of distribution: 0.9 L/kg; total clearance: 58.2 ml/min.,Clinical pharmacokinetics of lorazepam. Intramuscular injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13960/),[l] / [kg],0.9,203366,DB00186,Lorazepam
,13960,total clearance,Mean pharmacokinetic pamrameters for unchanged lorazepam were: apparent absorption half-life: 21.2 min; elimination half-life: 13.6 hr; volume of distribution: 0.9 L/kg; total clearance: 58.2 ml/min.,Clinical pharmacokinetics of lorazepam. Intramuscular injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13960/),[ml] / [min],58.2,203367,DB00186,Lorazepam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),min,20-90,206677,DB00186,Lorazepam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.3,206678,DB00186,Lorazepam
,2842128,bio-availability,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,16,206679,DB00186,Lorazepam
,2842128,half-life,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.7-1.3,206680,DB00186,Lorazepam
,2842128,plasma,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206681,DB00186,Lorazepam
,2842128,blood clearance,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206682,DB00186,Lorazepam
,2842128,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,40,206683,DB00186,Lorazepam
,2842128,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),kg,0.6-1,206684,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.44,208117,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.47,208118,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],9.6,208119,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],7.1,208120,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],0.96,208121,DB00186,Lorazepam
,3155675,clearance,"In non-smoking vs smoking subjects, there was no significant difference in mean clearance of diazepam (0.44 vs 0.47 ml/min/kg), midazolam (9.6 vs 7.1 ml/min/kg), or lorazepam (0.96 vs 1.08 ml/min/kg).","Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3155675/),[ml] / [kg·min],1.08,208122,DB00186,Lorazepam
,30336720,volume of distribution,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[l] / [kg],0.69,211785,DB00186,Lorazepam
,30336720,elimination half-life,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),h,13.6,211786,DB00186,Lorazepam
,30336720,peak,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],7.4,211787,DB00186,Lorazepam
,30336720,trough concentrations,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],3.7,211788,DB00186,Lorazepam
,30336720,trough,"Noncompartmental modeling of lacosamide pharmacokinetics revealed significant extracorporeal removal, a volume of distribution of 0.69 L/kg, elimination half-life of 13.6 hours, and peak and trough concentrations of 7.4 and 3.7 mg/L, respectively (goal trough, 5-10 mg/L).",Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30336720/),[mg] / [l],5-10,211789,DB00186,Lorazepam
,11510627,time (tmax) to peak concentration (Cmax),"In young healthy volunteers, absorption of mizolastine is rapid with time (tmax) to peak concentration (Cmax) of about 1 hour.",Clinical pharmacokinetics of mizolastine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1,215900,DB00186,Lorazepam
,11510627,absolute bioavailability,The absolute bioavailability of mizolastine 10mg tablets is about 65%.,Clinical pharmacokinetics of mizolastine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),%,65,215901,DB00186,Lorazepam
,11510627,distribution half-life,Distribution is rapid with a mean distribution half-life of 1.5 to 1.9 hours.,Clinical pharmacokinetics of mizolastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,1.5 to 1.9,215902,DB00186,Lorazepam
,11510627,apparent volume of distribution,Mizolastine is >98% bound to serum albumin and the apparent volume of distribution is between I and 1.4 L/kg.,Clinical pharmacokinetics of mizolastine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [kg],I and 1.4,215903,DB00186,Lorazepam
,11510627,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) is 7.3 to 17.1 hours.,Clinical pharmacokinetics of mizolastine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),h,7.3 to 17.1,215904,DB00186,Lorazepam
,11510627,apparent oral clearance,"The apparent oral clearance after a repeated oral dose of 10mg is 6.02 L/h, with steady state reached from day 3 and no accumulation between days 1 and 7.",Clinical pharmacokinetics of mizolastine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510627/),[l] / [h],6.02,215905,DB00186,Lorazepam
,9673833,half-life,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),h,0.8 to 1.8,217533,DB00186,Lorazepam
,9673833,clearance,"Its half-life in children over 12 months is reported to be 0.8 to 1.8 hours, with a clearance of 4.7 to 19.7 ml/min/kg.",Clinical pharmacology of midazolam in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673833/),[ml] / [kg·min],4.7 to 19.7,217534,DB00186,Lorazepam
,4020379,elimination half-life,"Her elimination half-life for desipramine was found to be greatly prolonged, at approximately 150 hours.",Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4020379/),h,150,220633,DB00186,Lorazepam
,22050870,clearance,"The population pharmacokinetics parameters were: clearance, 1.2 mL/min/kg; half-life, 16.8 hours; and volume of distribution, 1.5 L/kg.",Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22050870/),[ml] / [kg·min],1.2,221162,DB00186,Lorazepam
,22050870,half-life,"The population pharmacokinetics parameters were: clearance, 1.2 mL/min/kg; half-life, 16.8 hours; and volume of distribution, 1.5 L/kg.",Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22050870/),h,16.8,221163,DB00186,Lorazepam
,22050870,volume of distribution,"The population pharmacokinetics parameters were: clearance, 1.2 mL/min/kg; half-life, 16.8 hours; and volume of distribution, 1.5 L/kg.",Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22050870/),[l] / [kg],1.5,221164,DB00186,Lorazepam
,22050870,maximum initial dose,Age-dependent dosing is not necessary beyond using a maximum initial dose of 4 mg.,Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22050870/),,4,221165,DB00186,Lorazepam
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,58,222575,DB00186,Lorazepam
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,49,222576,DB00186,Lorazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.20,222577,DB00186,Lorazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.24,222578,DB00186,Lorazepam
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222579,DB00186,Lorazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222580,DB00186,Lorazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],5.63,222581,DB00186,Lorazepam
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],4.81,222582,DB00186,Lorazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,13.2,222583,DB00186,Lorazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,12.7,222584,DB00186,Lorazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.33,222585,DB00186,Lorazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.36,222586,DB00186,Lorazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,15.9,222587,DB00186,Lorazepam
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,18.5,222588,DB00186,Lorazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.1,222589,DB00186,Lorazepam
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.8,222590,DB00186,Lorazepam
,3472701,clearance,"We found an improvement in clearance of antipyrine (0.65 to 0.95 ml/min/kg; P less than 0.01) and lorazepam (0.93 to 1.20 ml/min/kg; P less than 0.05) in 12 of 14 patients, with a mean increase of 67% and 52%, respectively, from before to after remission.",Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],0.65 to 0.95,228150,DB00186,Lorazepam
,3472701,clearance,"We found an improvement in clearance of antipyrine (0.65 to 0.95 ml/min/kg; P less than 0.01) and lorazepam (0.93 to 1.20 ml/min/kg; P less than 0.05) in 12 of 14 patients, with a mean increase of 67% and 52%, respectively, from before to after remission.",Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],0.93 to 1.20,228151,DB00186,Lorazepam
,3472701,clearance,There was no significant difference in mean indocyanine green clearance from before to after induction (14.8 vs. 14.4 ml/min/kg).,Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],14.8,228152,DB00186,Lorazepam
,3472701,clearance,There was no significant difference in mean indocyanine green clearance from before to after induction (14.8 vs. 14.4 ml/min/kg).,Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3472701/),[ml] / [kg·min],14.4,228153,DB00186,Lorazepam
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.7,235671,DB00186,Lorazepam
,6827475,elimination T1/2,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,10.9,235672,DB00186,Lorazepam
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.46,235673,DB00186,Lorazepam
,6827475,total metabolic clearance,Pharmacokinetic analysis indicated increased antipyrine elimination T1/2 during cimetidine treatment (16.7 vs. 10.9 hr; P less than .001) on the basis of decreased total metabolic clearance (0.46 vs. 0.72 ml/min/kg; P less than .001).,Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.72,235674,DB00186,Lorazepam
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,58,235675,DB00186,Lorazepam
,6827475,T1/2,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,39,235676,DB00186,Lorazepam
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.42,235677,DB00186,Lorazepam
,6827475,total metabolic clearance,"Likewise, diazepam T1/2 was increased (58 vs. 39 hr; P less than .01) during cimetidine treatment due to decreased total metabolic clearance (0.42 vs. 0.30 ml/min/kg; P less than .01).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],0.30,235678,DB00186,Lorazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,16.8,235679,DB00186,Lorazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,15.3,235680,DB00186,Lorazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.03,235681,DB00186,Lorazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],1.07,235682,DB00186,Lorazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.66,235683,DB00186,Lorazepam
,6827475,T1/2,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),h,2.60,235684,DB00186,Lorazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.8,235685,DB00186,Lorazepam
,6827475,clearance,"In contrast, cimetidine did not alter T1/2 or the clearance of lorazepam (T1/2, 16.8 vs. 15.3 hr; clearance, 1.03 vs 1.07 ml/min/kg) or acetaminophen (T1/2, 2.66 vs. 2.60 hr; clearance, 4.8 vs. 4.5 ml/min/kg), both drugs which undergo conjugative biotransformation.",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[ml] / [kg·min],4.5,235686,DB00186,Lorazepam
,6827475,LD50,"In an animal model used to assess the effect of cimetidine on acetaminophen toxicity, the LD50 of acetaminophen alone in Charles River CD-1 mice was 480 mg/kg (95% confidence interval: 436-528 mg/kg).",Differential effect of cimetidine on drug oxidation (antipyrine and diazepam) vs. conjugation (acetaminophen and lorazepam): prevention of acetaminophen toxicity by cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6827475/),[mg] / [kg],480,235687,DB00186,Lorazepam
,2896126,volume of distribution,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),[l] / [kg],1.71,236519,DB00186,Lorazepam
,2896126,elimination half-life,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,113,236520,DB00186,Lorazepam
,2896126,total clearance,"Mean kinetic variables for intravenous chlordesmethyldiazepam were: volume of distribution, 1.71 l.kg-1; elimination half-life, 113 h; total clearance, 0.21 ml.min-1.kg-1; cumulative excretion of lorazepam glucuronide 24.2% of the dose.",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),[ml] / [kg·min],0.21,236521,DB00186,Lorazepam
,2896126,lag time,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),min,15.5,236522,DB00186,Lorazepam
,2896126,lag time,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),min,4.2,236523,DB00186,Lorazepam
,2896126,apparent absorption half-life,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,1.5,236524,DB00186,Lorazepam
,2896126,apparent absorption half-life,"Following a lag time of 15.5 min (tablets) and 4.2 min (drops), which were significantly different, the absorption of oral chlordesmethyldiazepam was a first order process, with apparent absorption half-life values averaging 1.5 h (tablets) and 1.1 h (drops).",Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),h,1.1,236525,DB00186,Lorazepam
,2896126,Bioavailability,Bioavailability was 77% for tablets and 79% for drops.,Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),%,77,236526,DB00186,Lorazepam
,2896126,Bioavailability,Bioavailability was 77% for tablets and 79% for drops.,Pharmacokinetics and bioavailability of intravenous and oral chlordesmethyldiazepam in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2896126/),%,79,236527,DB00186,Lorazepam
,1868674,clearance,"Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area.",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [kg·min],0.91,238623,DB00186,Lorazepam
,1868674,clearance,"Antipyrine clearance normalized to body weight was significantly greater in children than in adults (0.91 versus 0.59 ml/min/kg; p = 0.012), but was not different when normalized to body surface area.",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [kg·min],0.59,238624,DB00186,Lorazepam
,1868674,CL,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],31.9,238625,DB00186,Lorazepam
,1868674,CL,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],40.6,238626,DB00186,Lorazepam
,1868674,CLu,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],352,238627,DB00186,Lorazepam
,1868674,CLu,"In contrast, lorazepam total clearance (CL) and unbound clearance (CLu) normalized to body weight were not significantly different between children and adults but were smaller in children when normalized to body surface area (CL = 31.9 versus 40.6 ml/min/m2, p = 0.036; CLu = 352 versus 485 ml/min/m2, p = 0.010).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),[ml] / [m2·min],485,238628,DB00186,Lorazepam
,1868674,fraction unbound,"The mean lorazepam fraction unbound in children was 0.087, which was not different from adult volunteers (0.084).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),,0.087,238629,DB00186,Lorazepam
,1868674,fraction unbound,"The mean lorazepam fraction unbound in children was 0.087, which was not different from adult volunteers (0.084).",Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1868674/),,0.084,238630,DB00186,Lorazepam
,6713774,Cls,"After single doses, t1/2 and V beta increased in patients, but Cls in the patients (about 85 ml/min) did not differ significantly from that in normals (71 ml/min).",Effect of renal impairment and hemodialysis on lorazepam kinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713774/),[ml] / [min],85,240464,DB00186,Lorazepam
,6713774,Cls,"After single doses, t1/2 and V beta increased in patients, but Cls in the patients (about 85 ml/min) did not differ significantly from that in normals (71 ml/min).",Effect of renal impairment and hemodialysis on lorazepam kinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713774/),[ml] / [min],71,240465,DB00186,Lorazepam
more,6713774,Absorption of oral dose,Absorption of oral dose was more than 90% and was not impaired by the disease state.,Effect of renal impairment and hemodialysis on lorazepam kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713774/),%,90,240466,DB00186,Lorazepam
,17940637,elimination half-life,It has a mean elimination half-life of 6.3 hours.,"Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17940637/),h,6.3,244022,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],4.13,246815,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.42,246816,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 4.13 - (PEEP - 5) x 0.42 l h-1, and 0.74 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.74,246817,DB00186,Lorazepam
,14748812,volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,0.74,246818,DB00186,Lorazepam
,14748812,steady state volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,56,246819,DB00186,Lorazepam
,14748812,steady state volume of distribution,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,2.1,246820,DB00186,Lorazepam
,14748812,intercompartmental clearance,"The volume of distribution was 0.74 l, the steady state volume of distribution was 56 - (age - 58) x 2.1 l and the intercompartmental clearance was 10 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],10,246821,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],11.3,246822,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.14,246823,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],7.27,246824,DB00186,Lorazepam
,14748812,Total body clearance,"Total body clearance for patients without alcohol abuse was 11.3 - (age - 57) x 0.14 l h-1, and 7.27 - (age -57) x 0.14 l h-1 for patients with alcohol abuse.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],0.14,246825,DB00186,Lorazepam
,14748812,volume of distribution,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,7.15,246826,DB00186,Lorazepam
,14748812,steady state volume of distribution,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),l,431,246827,DB00186,Lorazepam
,14748812,intercompartmental clearance,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],40.8,246828,DB00186,Lorazepam
,14748812,intercompartmental clearance,"The volume of distribution was 7.15 l, the steady state volume of distribution was 431 l, and the intercompartmental clearance was 40.8 - (APACHE score - 26) x 2.75 l h-1.",Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748812/),[l] / [h],2.75,246829,DB00186,Lorazepam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],68,247242,DB00186,Lorazepam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],101,247243,DB00186,Lorazepam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],208,247244,DB00186,Lorazepam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],304,247245,DB00186,Lorazepam
,11506097,"C50,ss","The predicted C50,ss (plasma benzodiazepine concentrations where P(Sedation > or = ss) = 50%) values for midazolam (sedation score [SS] > or = n, where n = a Ramsay Sedation Score of 2, 3, ... 6) were 68, 101, 208, 304, and 375 ng/ml.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],375,247246,DB00186,Lorazepam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],34,247247,DB00186,Lorazepam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],51,247248,DB00186,Lorazepam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],104,247249,DB00186,Lorazepam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],152,247250,DB00186,Lorazepam
,11506097,"C50,ss","The corresponding predicted C50,ss values for lorazepam were 34, 51, 104, 152, and 188 ng/ml, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),[ng] / [ml],188,247251,DB00186,Lorazepam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,3.6,247252,DB00186,Lorazepam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,14.9,247253,DB00186,Lorazepam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,11.9,247254,DB00186,Lorazepam
,11506097,emergence times from sedation,"The predicted emergence times from sedation after a 72-h benzodiazepine infusion for light (SS = 3) and deep (SS = 5) sedation in a typical patient were 3.6 and 14.9 h for midazolam infusions and 11.9 and 31.1 h for lorazepam infusions, respectively.","A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506097/),h,31.1,247255,DB00186,Lorazepam
,2926577,systemic clearance,"Mean (+/- SD) lorazepam systemic clearance was 1.3 +/- 0.4 ml/min/kg, with a terminal half-life of 10.5 +/- 2.9 hours and an unbound clearance of 15.9 +/- 5.2 ml/min/kg.",Lorazepam pharmacodynamics and pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2926577/),[ml] / [kg·min],1.3,250306,DB00186,Lorazepam
,2926577,terminal half-life,"Mean (+/- SD) lorazepam systemic clearance was 1.3 +/- 0.4 ml/min/kg, with a terminal half-life of 10.5 +/- 2.9 hours and an unbound clearance of 15.9 +/- 5.2 ml/min/kg.",Lorazepam pharmacodynamics and pharmacokinetics in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2926577/),h,10.5,250307,DB00186,Lorazepam
,2926577,unbound clearance,"Mean (+/- SD) lorazepam systemic clearance was 1.3 +/- 0.4 ml/min/kg, with a terminal half-life of 10.5 +/- 2.9 hours and an unbound clearance of 15.9 +/- 5.2 ml/min/kg.",Lorazepam pharmacodynamics and pharmacokinetics in children. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2926577/),[ml] / [kg·min],15.9,250308,DB00186,Lorazepam
,2926577,systemic clearance,"A group of healthy adult volunteers who were given lorazepam had a mean systemic clearance of 1.0 +/- 0.4 ml/min/kg, somewhat less than that of the children (p = 0.069).",Lorazepam pharmacodynamics and pharmacokinetics in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2926577/),[ml] / [kg·min],1.0,250309,DB00186,Lorazepam
,2858217,elimination half-life,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,43,251538,DB00186,Lorazepam
,2858217,elimination half-life,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,38,251539,DB00186,Lorazepam
,2858217,total clearance,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.41,251540,DB00186,Lorazepam
,2858217,total clearance,"For diazepam, propoxyphene produced a small and statistically insignificant prolongation of elimination half-life (43 vs 38 h) and reduction of total clearance (0.41 vs 0.47 ml min-1 kg-1).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.47,251541,DB00186,Lorazepam
,2858217,half-life,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,18,251542,DB00186,Lorazepam
,2858217,half-life,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,12,251543,DB00186,Lorazepam
,2858217,total clearance,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],0.8,251544,DB00186,Lorazepam
,2858217,total clearance,"Propoxyphene significantly prolonged alprazolam half-life (18 vs 12 h, P less than 0.005) and reduced total clearance (0.8 vs 1.3 ml min-1 kg-1, P less than 0.005).","Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.3,251545,DB00186,Lorazepam
,2858217,half-life,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,13.4,251546,DB00186,Lorazepam
,2858217,half-life,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),h,13.5,251547,DB00186,Lorazepam
,2858217,clearance,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.5,251548,DB00186,Lorazepam
,2858217,clearance,Propoxyphene had no apparent influence on lorazepam half-life (13.4 vs 13.5 h) or clearance (1.5 vs 1.4 ml min-1 kg-1).,"Interaction of propoxyphene with diazepam, alprazolam and lorazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2858217/),[ml] / [kg·min],1.4,251549,DB00186,Lorazepam
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],73.6,256672,DB00186,Lorazepam
,9788577,AUCs,"Median AUCs of cyclophosphamide in patients receiving ondansetron (73.6 mg/ml x min) were lower than those of the control patients (88.3 mg/ml x min, n = 75, P = 0.0004), but the median cisplatin AUC was approximately 10% higher and no difference in the disposition of carmustine was demonstrated.",Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9788577/),[mg] / [min·ml],88.3,256673,DB00186,Lorazepam
,4030162,t1/2a,"While no consistent temporal changes in any parameter characterizing elimination of lorazepam were observed, absorption constant rate (Ka) and absorption half-life (t1/2a) were significantly modified by the hour of administration, the drug being more rapidly absorbed after the morning (t1/2a = 0.52 +/- 0.11) than after the morning trial (t1/2a = 1.18 +/- 0.26, p less than 0.05).",Temporal variations of lorazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030162/),,0.52,260727,DB00186,Lorazepam
,4030162,t1/2a,"While no consistent temporal changes in any parameter characterizing elimination of lorazepam were observed, absorption constant rate (Ka) and absorption half-life (t1/2a) were significantly modified by the hour of administration, the drug being more rapidly absorbed after the morning (t1/2a = 0.52 +/- 0.11) than after the morning trial (t1/2a = 1.18 +/- 0.26, p less than 0.05).",Temporal variations of lorazepam pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030162/),,1.18,260728,DB00186,Lorazepam
,3346841,plasma half-life,Interruption of the EHC caused lorazepam plasma half-life to shorten (3.4 vs.,Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),,3.4,264761,DB00186,Lorazepam
,3346841,clearance to,"2.3 hr with the EHC intact, P less than .1), clearance to increase (9.2 vs.",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),,9.2,264762,DB00186,Lorazepam
,3346841,total area under the plasma concentration curve,"12.3 ml/min/kg, P less than .1) and total area under the plasma concentration curve for lorazepam glucuronide to decrease (210 vs. 310 ng/ml X hr, P less than .06).",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),[ng] / [h·ml],210,264763,DB00186,Lorazepam
,3346841,total area under the plasma concentration curve,"12.3 ml/min/kg, P less than .1) and total area under the plasma concentration curve for lorazepam glucuronide to decrease (210 vs. 310 ng/ml X hr, P less than .06).",Enterohepatic circulation of lorazepam and acetaminophen conjugates in ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3346841/),[ng] / [h·ml],310,264764,DB00186,Lorazepam
,3360972,half-life,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),h,23,267062,DB00186,Lorazepam
,3360972,half-life,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),h,16,267063,DB00186,Lorazepam
,3360972,clearance,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),[ml] / [kg·min],.28,267064,DB00186,Lorazepam
,3360972,clearance,"Compared with control, metronidazole significantly prolonged phenytoin half-life (23 versus 16 hours, P less than .02) and reduced its clearance (.28 versus .33 mL/min/kg, P less than .005), known to depend on aromatic hydroxylation.",Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360972/),[ml] / [kg·min],.33,267065,DB00186,Lorazepam
,16908225,flow rate,"The mobile phase consisting of a mixture of acetonitrile, 10 mmol/l ammonium acetate and formic acid (60:40:0.1, v/v/v) was delivered at a flow rate of 0.5 ml/min.",Determination of metolazone in human blood by liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16908225/),[ml] / [min],0.5,271147,DB00186,Lorazepam
